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In the encyclopedia of health and aging, hypertension is described as a “persistent elevation 
of arterial blood pressure”.1 With aging, the arterial structure and function change, which 
eventually can result in hypertension.2 Systolic blood pressure (SBP) increases linearly with 
increasing age, while diastolic blood pressure (DBP) starts to decrease above the age of 60 
years. Both systolic and diastolic blood pressure are associated with increased stiffness of 
the large arteries.3 
The population is aging and hypertension is observed in the majority of elderly people, 
which is a major concern for health care. Worldwide, hypertension in the adult population is 
prevalent in approximately 26%, with the prevalence expected to increase to 29% by 2025.4 
An even higher prevalence with a mean of 44% across six European countries has been 
reported already in the 1990’s.5 In 2010, in a Dutch population of elderly individuals (60-
70 years), hypertension was prevalent in 62% of men and in 55% of women, increasing 
to approximately 70% for both men and women aged between 70 and 80 years.6 The 
Framingham study showed that for adults aged 55 years, the lifetime risk of developing 
hypertension was 90%.7 
Hypertension and cardiovascular disease
Hypertension has been defined as a SBP of ≥140 mmHg and/or a DBP of ≥90 mmHg 
(stage/grade 1 hypertension), while a SBP of ≥160 mmHg and/or a DBP of ≥100 mmHg is 
defined as stage/grade 2 hypertension according to the American Heart Association (AHA), 
and the European Society of Hypertension/European Society of Cardiology guidelines.8,9 
Hypertension is a major risk factor for the onset of cardiovascular disease, including coronary 
artery disease, heart failure, and stroke.10 A self-reported history of hypertension has been 
shown to be the most important risk factor for stroke (including all subtypes).11 However, 
within the scope of this thesis, we will mainly focus on hypertension in relation to cardiac 
dysfunction. The risk for ischemic heart disease mortality as well as other vascular mortality 
increases linearly with increasing blood pressure.12 The Framingham Heart Study has shown 
that for individuals with a blood pressure exceeding 160/100 mmHg the lifetime risk for 
heart failure is approximately two times higher as compared to individuals with a blood 
pressure of less than 140/90 mmHg.13 A meta-analysis has shown that for hypertensive 
patients aged between 40 and 69 years, an increase of 20 mmHg starting at a SPB of 115 
mmHg is associated with a twofold increase in cardiovascular death rates.12 Although other 
factors also contribute to the development of heart failure, myocardial infarction (MI) is 
associated with the largest risk for development of heart failure. However, hypertension 
has the largest population-attributable risk because of its high prevalence.14 Hypertension 
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leads to an increased hemodynamic burden on the myocardium,15 and is  associated with 
MI and changes in the (left) ventricular structure, and may finally evolve into heart failure.2 
As summarized in an overview of Vasan and Levy,16 hypertension is the most important 
risk factor for left ventricular hypertrophy (LVH), which in turn may result in left ventricular 
diastolic dysfunction. Furthermore, LVH is an important risk factor for MI, which is associated 
with left ventricular systolic dysfunction. Both asymptomatic left ventricular systolic and 
diastolic dysfunction can evolve into clinical chronic heart failure, which underlines the key 
role of hypertension in the development of heart failure (figure 1), as well as the importance 
of early diagnosis and adequate interventions.16 
 Figure 1. Progression from hypertension to heart failure, figure adapted from Vasan and Levy.16
LVH, left ventricle hypertrophy; MI, myocardial infarction; HF, heart failure
A review by Allen et al., showed that lowering blood pressure is related to a reduced risk of 
major cardiovascular events.17 In case of high blood pressure at 55 years of age, a decrease 
in blood pressure is associated with a lower lifetime risk for cardiovascular disease (CVD) 
and/or coronary heart disease (CHD), while an increase of blood pressure beyond this age 
is associated with an increased lifetime risks for CVD and CHD.18 Previous research showed 
that in elderly patients SBP is more predictive of mortality and cardiovascular events than 
DBP. Therefore, treatment of blood pressure with antihypertensive medication should be 
directed towards lowering the SBP.19 In agreement with these findings, in the Dutch guideline 
on cardiovascular risk management (CVRM) developed by the Dutch College of General 
Practitioners, generally a target SBP of ≤140 mmHg is advised.20 However, achieving optimal 
blood pressure control in hypertension patients in primary care is difficult.21 A previous 
study reported adequate blood pressure control between 23% and 38% of hypertension 
patients in 5 European countries.21 A Spanish study showed that optimal blood pressure 
control is achieved in approximately 40% of patients above the age of 65,22 while a Danish 
study showed adequate blood pressure control in only 33% of primary care patients,23 with 

















Cardiovascular risk management and hypertension 
On April 7 2013, the WHO released the report “A global brief on hypertension”. The prevention 
and control of hypertension is described as one of the keys to reduce death and disability 
from noncommunicable diseases.27 Currently integrated guidelines focusing on CVRM, 
such as the 2010 American College of Cardiology (ACC) / AHA Guideline for Assessment 
of Cardiovascular Risk in Asymptomatic Adults, strongly focus on initial assessment of risk 
factors in apparently healthy individuals in order to prevent CVD.28 Since 2006, the Dutch 
unifactorial guidelines on hypertension and hypercholesterolemia have been integrated into 
one multidisciplinary guideline on CVRM.29 This guideline focuses on a risk profile using the 
SCORE criteria10 - a risk scoring system for use in the clinical management of cardiovascular 
risk - in which systolic blood pressure plays a major role.20 The SCORE criteria include systolic 
blood pressure, gender, age, cholesterol (total or total/HDL ratio), and smoking, in order to 
calculate a percentage for the estimation of the total cardiovascular risk.10 
In the Netherlands, during the last decade, large primary care groups have been founded 
in which general practitioners (GPs) and practice nurses (PN) collaborate according to 
standardized protocols. There are now around 100 primary care groups operational in 
the Netherlands, varying in size from 10 to over 200 GPs. PoZoB is an example of a large 
primary care group (150 GPs responsible for the primary care of 350.000 patients) located 
in the South-East of the Netherlands. The patient population is predominantly living in a 
semi-rural area. In 2010, PoZoB initiated a CVRM program in which currently almost 45.000 
patients with one or more risk factors for a (primary or secondary) cardiovascular event are 
prospectively followed by a PN according to a Dutch guideline on CVRM developed by the 
Dutch College of General Practitioners.20 The purpose of this CVRM program is to prevent 
the development of a primary cardiovascular event in high-risk patients according to the 
SCORE criteria, and to prevent a secondary event in patients with established CVD.10 The 
SCORE project used pooled datasets from 12 European countries to construct risk charts 
which predict the ten-year risk of fatal CVD by using age, gender, smoking, mean cholesterol, 
and mean SBP.10 In the CVRM program, patients who meet the SCORE criteria are included. 
Since hypertension is highly prevalent, especially in the elderly6, these patients represent a 
large proportion of the patients included in the CVRM program. 
The Dutch guideline on CVRM - applied in the CVRM program of PoZoB - recommends a 
target SBP of ≤140 mmHg in patients with hypertension below 80 years of age. In patients 
aged 80 years or older, a target SBP of ≤160 mmHg is recommended, while for type 2 
diabetic patients the target SBP is ≤130 mmHg.20 Lowering blood pressure, also in patients 
above 55 years of age, is important to reduce the risk of cardiovascular events.18 However, 
more information on the status of blood pressure control in Dutch primary care in relation 




The Dutch guideline on CVRM recommends diuretics as medication of first choice in the 
treatment of hypertension, with calcium channel blockers (CCB) as second option in case 
of adverse effects of diuretics. However, angiotensin converting enzyme (ACE) inhibitors 
as well as angiotensin II receptor blockers (ARBs) are equally effective for the prevention 
of cardiovascular events as compared to CCBs and diuretics.30 As a second step, the 
combination of a diuretic and an ACE-inhibitor can be considered, with replacement by 
an ARB in case of adverse effects. Third, a combination of a diuretic with an ACE-inhibitor 
or ARB, and a CCB would be recommended. In case of intolerance to one of the above 
described antihypertensive medications, a beta-blocker can be considered as a sufficient 
alternative, although accompanying adverse effects of beta-blockers, which are common, 
should be taken into consideration.20 
The role of beta-blockers has been reduced in the current guidelines, because several 
studies have shown that beta-blockers are less effective in reducing cardiovascular risk.30 
However, beta-blockers are still strongly recommended in patients with prior MI.20,31 Despite 
the availability of effective medication, hypertension remains a risk factor for heart failure, 
which can partly be attributed to inadequate drug prescription and partly to sub-optimal 
compliance of patients. Persistent use of antihypertensive medication is an important 
determinant of lowering blood pressure.32 Therefore, an overview of the current status of 
blood pressure control in Dutch primary care in relation to the recommendations in the 
CVRM guideline could provide valuable information. 
Screening for cardiac dysfunction
Symptomatic heart failure is generally preceded by asymptomatic cardiac dysfunction or 
changes in cardiac structure such as LVH.33,34 Recent guidelines of the ACC and the AHA 
describe four stages of heart failure, including not only symptomatic but also the preceding 
asymptomatic stages. Stage A includes patients with only risk factors for the development 
of heart failure, including hypertension; stage B includes asymptomatic cardiac dysfunction; 
stage C includes overt heart failure; and stage D represents end-stage heart failure.33,35 The 
transition from the asymptomatic stage B to the symptomatic stage C is associated with a 
sharp (5-fold) decrease in five-year survival,33 suggesting the importance of early detection 
of cardiac dysfunction and adequate treatment of risk factors (Table 1).
According to the ACC and AHA 2010 guidelines on CVRM, early assessment of cardiovascular 
risk can provide a basis for individualized efforts to prevent CVD.28 A scientific statement 
from the AHA published in 2008 recommends that future studies should focus on the 




heart failure).36 Furthermore, in the 2011 ACC and AHA expert consensus document on 
hypertension in the elderly, echocardiography is considered to be a useful tool to evaluate 
LVH and left ventricular dysfunction in ‘selected’ elderly persons. However, criteria for this 
selection are not delineated.2 In previous studies, echocardiography has been recommended 
for the detection of both LVH and left ventricular systolic dysfunction in patients at risk for 
heart failure.37,38 Moreover, not only LVH, diastolic, and systolic dysfunction are associated 
with heart failure, but also valvular heart disease and wall motion abnormalities can 
contribute to the development of heart failure and are related to CHD.39,40 Echocardiography 
is seen as the gold standard for confirming a diagnosis and establishing the cause of heart 
failure.35,41 The current guidelines on heart failure of the European Society of Cardiology 
considers echocardiography as a useful tool to assess chamber volumes, ventricular systolic 
and diastolic dysfunction, wall motion, wall thickness, and valvular function, which are 
all predictive of heart failure.41 Therefore, screening of elderly adults with hypertension 
by means of echocardiography could provide useful information for a treating physician. 
Although an echocardiogram is a cheap and non-invasive assessment with high sensitivity to 
detect cardiac abnormalities, it is not routinely used by the GP.42 Since blood pressure control 
in (elderly) hypertension patients is generally poor,21 these patients are likely to be at high 
risk for heart failure. Therefore, screening hypertension patients for asymptomatic cardiac 
dysfunction might provide insight into which patients are at higher risk for developing heart 
failure.
Table 1. Heart failure stages according to the ACC/AHA guidelines, adapted from Hunt et al.35
Stage Guideline description Including patients with (e.g.):
A At high risk for heart failure but without 





B Structural heart disease but without signs 
of symptoms of heart failure
Previous myocardial infarction
Left ventricle hypertrophy and/or low ejection fraction
Asymptomatic valvular disease
C Structural heart disease with prior or 
current symptoms of heart failure
Known structural heart disease
AND
Shortness of breath, fatigue, reduced exercise tolerance
D Refractory heart failure requiring 
specialized interventions
Symptoms at rest despite optimal medical therapy
Recurrent hospitalizations
ACC, American College of Cardiology; AHA, American Heart Association
Patient-reported symptoms
The majority of patients with possible heart failure will present themselves initially in 
primary care,43 therefore it is important for a GP or PN to be able to identify symptoms 
predictive of this condition. Previous research has shown that the value of symptoms is 
limited in the diagnosis of heart failure.44 Especially in early stages of heart failure, milder 
symptoms do occur which are generally insensitive for the diagnosis of heart failure.41 
14
Chapter 1
Frequently reported symptoms of heart failure are edema, dyspnea, and fatigue.45 These 
symptoms have also been found in primary care studies in patients with heart failure.42,43 
Prior findings have shown that symptoms such as fatigue and breathlessness in patients 
with heart failure are associated with adverse outcomes.46 However, most studies evaluating 
the value of symptoms in the diagnosis of heart failure have focused on populations 
treated in hospitals.47 Furthermore, the majority of studies evaluated symptoms only in 
association with left ventricular systolic dysfunction and did not evaluate the association of 
symptoms with other cardiac abnormalities associated with heart failure such as diastolic 
dysfunction.47 Information on heart failure symptoms in primary care hypertension patients 
could help in clinical practice to make a selection of patients who should be referred for 
further examination.
Psychological distress in hypertension patients
The 2012 European guidelines on cardiovascular disease prevention in clinical practice of 
the ESC and other societies on cardiovascular disease prevention state that psychological 
factors, such as depression, anxiety, and Type D personality (the tendency to experience 
negative emotions in combination with the tendency to inhibit the expression of emotions48), 
may contribute to the risk of developing CVD and may have impact on prognosis in patients 
with established disease.49 This statement is supported by previous research that has shown 
an association between psychological distress such as depression,50,51 anxiety,52 and Type D 
personality,53 and the incidence and/or prognosis of cardiac diseases such as CHD and heart 
failure. Furthermore, a systematic review showed an increased incidence of hypertension in 
participants with elevated symptoms of depression.54 However, the Dutch guideline on CVRM 
does not explicitly include attention to psychological distress in their recommendations, 
although it is stated that especially work-related stress might be an important factor that 
might increase cardiovascular risk.20
Focus on psychological distress, such as depression or anxiety, in hypertension patients is 
relevant because psychological distress could be a possible barrier for adequate adherence 
to medication.55 In general, adherence is seen as an important aspect of hypertension 
treatment, with non-adherence as one of the possible causes of resistant hypertension.8 
Prior findings have shown an independent association between poor medication adherence 
in elderly patients with hypertension and depression and/or anxiety.55 However, other 
studies reported mixed or inconclusive results,56 or found no relation between the level of 
blood pressure and psychological distress.57 Most studies investigating a possible relation 
between psychological distress and CVD focused on out-patient clinic or hospital patients. 
Data of primary care populations are scarce. Therefore, more information is needed on the 




conclude whether a focus on psychological distress in CVRM of hypertension patients is 
required. 
There is an ongoing debate whether beta-blockers may be associated with (symptoms of) 
depression.58 Lipophilic beta-blockers, such as metoprolol, can pass the blood-brain barrier 
and are most likely associated with adverse effects related to the central nervous system 
such as depression and fatigue.59 Beta-blockers are still prescribed frequently in primary care 
hypertension patients, although the current CVRM guideline advises other antihypertensive 
medication as first choice treatment.20 Evidence for an association between beta-blocker 
use and depression is inconclusive. Many studies, as described in a review on the association 
between beta-blockers and depression, were subject to methodological shortcomings that 
might explain the mixed results.58 Also some recent studies with good methodological quality 
showed mixed findings.60-63 However, these studies were mainly conducted in patients in 
whom beta-blockers are strongly recommended (e.g. patients with a prior MI63, or patients 
with an implantable cardioverter defibrillator61), while currently no studies have examined 
the association between beta-blocker and depression in primary care hypertension patients.
Aims and outline of the thesis
This thesis presents the results of a study evaluating several aspects associated with CVRM 
in primary care hypertension patients aged between 60 and 85 years. The general aim of 
this thesis is to gain more insight into the clinical and psychological aspects associated with 
CVRM in elderly hypertension patients in primary care.  
Hypertension management is an important part of CVRM as described in the Dutch 
guideline on CVRM. However, more information on the association between adherence to 
the guideline in relation to cardiovascular abnormalities diagnosed with echocardiography 
could be of great value. Therefore, chapter 2 describes treatment of uncomplicated 
hypertension in primary care according to the Dutch guideline on CVRM and the association 
with abnormalities on an echocardiogram.
Little is known about cardiac dysfunction in unselected elderly patients with hypertension. 
Therefore, in chapter 3 the prevalence of cardiac abnormalities assessed by echocardiography 
is described. Furthermore, in that chapter the association between SBP and cardiac 
abnormalities is evaluated.
Hypertension is an important risk factor for heart failure,64 and most patients with possible 
heart failure will present themselves initially in primary care.43 The prevalence of symptoms 
such as shortness of breath, fatigue, and edema in unselected elderly hypertension patients 
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is unknown, as well as the value of symptoms in the diagnosis of cardiac abnormalities 
assessed with echocardiography. In chapter 4 the prevalence of heart failure symptoms 
is described, as well as the value of these symptoms in association with an abnormal 
echocardiogram in elderly primary care hypertension patients.
Until recently, the majority of research on the relation between psychological distress and 
cardiovascular risk has focused on patients being treated in hospital or outpatient-clinics. 
Previous findings on the association between psychological distress and hypertension are 
mixed. The objective of chapter 5 was therefore to describe the prevalence of depression, 
anxiety, and Type D personality in primary care hypertension patients, and to study the 
association between psychological distress and SBP taking into account several confounders. 
Although the prescription of beta-blockers for uncomplicated hypertension is no longer 
recommended in the current guidelines, they are still frequently prescribed in primary 
care hypertension patients.20 Previous research has shown mixed findings on the possible 
association between beta-blocker use and depression, although these studies often had 
methodological shortcomings. Chapter 6 describes the association of lipophilic beta-
blockers with depression in primary care hypertension patients.
Finally, in chapter 7 the main findings of this thesis are summarized and strengths and 
limitations, clinical implications of the findings, and directions for future research are 
discussed. 
Research design
The data reported on in this thesis were collected as part of the CHELLO (Casefinding 
Hartfalen EersteLijns Longitudinaal Onderzoek) study. CHELLO is a study on the screening 
of elderly primary care hypertension patients for cardiac abnormalities. Between June 2010 
and January 2013, five different GP practices affiliated with the primary care organization 
PoZoB participated in this study. During this period, the CVRM program started within PoZoB 
and the sample selected for the CHELLO study was embedded within this program.
Inclusion criteria
Patients between 60 and 85 years of age with diagnosed hypertension according to the 
International Classification of Primary Care (ICPC) code K86 (primary hypertension without 
organ damage) and/or ICPC K87 (primary hypertension with organ damage) in their medical 





Patients were excluded in case of a previous diagnosis of heart failure and/or treatment 
by a cardiologist at the time of inclusion (patients with previous CHD, not being seen by a 
cardiologist were eligible for study participation); a history of severe psychiatric illness other 
than mood or anxiety disorders; cognitive impairments (e.g. dementia) determined by the 
GP; terminal cancer; insufficient knowledge of the Dutch language or inability to read.
Table 2. Content of the interview, baseline variables, and examination
Variables Source
Demographics
Age Purpose designed questions
Gender Purpose designed questions
Marital status Purpose designed questions
Education level Purpose designed questions
Employment status Purpose designed questions
Clinical variables and risk factors
Symptoms of heart failure Standardized questionnaire
Height Measurement
Weight Measurement
Systolic and diastolic blood pressure Measurement (after 20 and 40 minutes of resting)
Current smoking Purpose designed questions
Alcohol consumption Purpose designed questions
Comorbidities
Previous MI Review of medical record
Peripheral arterial disease Review of medical record
Previous CVA / TIA Review of medical record
Asthma or COPD Review of medical record







Review of medical record
Psychological variables
Depression (PHQ-9) Validated questionnaire
Anxiety (GAD-7) Validated questionnaire
Type D personality (DS14) Validated questionnaire
MI, myocardial infarction; CVA, cerebrovascular accident; TIA, transient ischemic attack; ACE, angiotensin 
converting enzyme; ARB, angiotensin receptor blocker; PHQ-9,9-item Patient Health Questionnaire; GAD-7, 
7-item Generalized Anxiety Disorder; DS, Distressed Scale
18
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Study procedure and data collection
Eligible patients (n=913) received information about the study both orally and in writing, 
and were asked to sign an informed consent that was sent by postal mail. Within three 
weeks patients were contacted by phone, and in case of informed consent an appointment 
for an interview at the local GP office was scheduled. During this first appointment, eligible 
patients underwent a structured interview (Table 2).
Assessment of cardiac function with electrocardiography and echocardiography
The electrocardiogram (ECG) and echocardiogram were carried out by a trained and 
experienced echocardiographist of the local Primary Care Laboratory of the city of Eindhoven, 
“Diagnostiek voor U”. All the electrocardiograms and echocardiograms were reviewed by a 
cardiologist specialized in echocardiography.
A standard resting 12-lead ECG was recorded. ECG characteristics and abnormalities studied 
included heart rate, arrhythmias (atrial fibrillation), conduction abnormalities (left bundle 
branch block, left fascicular block, atrio-ventricular conduction), left and right ventricular 
hypertrophy, ischemic heart disease, and (prior) myocardial infarction.
Echocardiograms were made with the Philips CX 50 equipped with a cardiology package and 
an s5 transducer. The echocardiogram was classified as abnormal according to the criteria as 
shown in Table 3. Furthermore, ten echocardiograms (randomly selected) were performed 
together with a cardiologist who observed whether the echocardiographist accurately 
followed the prescribed protocol. 
Table 3. Categories of cardiac abnormalities on the echocardiogram
Category Cut-off
LVEF <55%65
LVH Septal and posterior wall thickness of ≥ 13 mm (moderate or severe65)
LAVI >29 ml/m² 65
Diastolic dysfunction E/A ratio of <1 and deceleration times of >200ms, and presence of LVH in case 
of grade I diastolic dysfunction66
RVH Subcostal wall thickness of  ≥6mm  (mild, moderate or severe)
Aortic valve insufficiency Moderate or severe abnormalities, AI P1/2 time 
Aortic valve stenosis Mean gradient ≥ 30 mmHg
Mitral valve insufficiency Moderate or severe abnormalities, grade 2 or higher
MAC Presence of MAC
Tricuspid valve insufficiency Moderate or severe abnormalities, grade 2 or higher
Wall motion abnormalities Hypokinesia, akinesia and dyskinesia
Aortic dilatation Moderate or severe abnormalities, >40mm
Cardiomyopathy Hypertrophic cardiomyopathy
Congenital abnormalities Atrial septal defect, bicuspid aortic valve
LVEF, left ventricular ejection fraction; LVH, left ventricle hypertrophy; LAVI, left atrium volume index; MAC, mitral 




An adapted protocol was used to assess cardiac abnormalities on the echocardiogram 
suitable for use in general practice. The Simpson formula was used to calculate left ventricular 
ejection fraction (LVEF) in the apical four-chamber and apical two-chamber view.65 LVH was 
calculated with measurement of septal and posterial wall thickness and left atrial volume 
index (LAVI) was calculated with left atrial volume/body surface area (ml/m2).65 In individuals 
aged >60 years without a history of CVD, an E/A ratio of <1 and DTs of >200ms are common, 
therefore, diastolic dysfunction was considered when also LVH was present in case of grade 
I diastolic dysfunction.66 Right ventricle hypertrophy was calculated with measurement of 
right ventricle subcostal wall thickness.67 Aortic valve insufficiency, aortic valve stenosis, 
mitral valve insufficiency, mitral valve stenosis, mitral annulus calcification (MAC), tricuspid 
valve insufficiency, wall motion abnormalities, aortic dilatation, cardiomyopathy, and 
congenital abnormalities were assessed (Table 3). The GP of the patient received the results 
of the echocardiogram and in case of a clinically relevant abnormal echocardiogram, the 
cardiologist advised the GP. The three different categories of advice were: 1) (immediate) 
referral to a cardiologist, 2) advice to repeat the echocardiogram within 1 to 5 years, and 3) 
advice to change the medication regimen.
Psychological measures 
The 14-item Type D Scale (DS14) was used to assess Type D personality, 7 items of this 
questionnaire assess negative affectivity (NA) and 7 items assess social inhibition (SI). Items 
are rated on a 5-point Likert scale (range 0-56). Previous research showed that the DS14 is 
a valid and reliable instrument to assess Type D personality.68  Both NA and SI scales can be 
used as continuous scales, and also to classify patients as ‘Type D’ versus ‘non-Type D’. A cut-
off of ≥10 on both subscales was found to be optimal according to Item Response Theory.69 
The 9-item Patient Health Questionnaire (PHQ-9) was used to assess symptoms of 
depression. Items are rated on a 4-point Likert scale (range 0-27).70 In this study, a cut off of 
≥9 was used which is suitable for elderly individuals in primary care, with a sensitivity of 88% 
and specificity of 80% and an area under the curve for the detection of a major depressive 
disorder of .87.71
Symptoms of anxiety were measured with the Generalized Anxiety Disorder-7 (GAD-7) scale. 
The seven items are rated on a 4-point Likert scale (range 0-21), and increasing scores are 
associated with functional impairment and disability.72 In this study, a cut-off of ≥8 was used 
since this has a high sensitivity (92%) and specificity (76%) for the detection of generalized 
anxiety disorder, as well as for the detection of any anxiety disorder (respectively 77% and 




Both the PHQ-9 and the GAD-7 are derived from the Primary Care Evaluation of Mental 
Disorders (PRIME-MD), which was originally designed for the diagnosis of five mental 





1. Amador LF. Hypertension. In: Markides KS, 
ed. Encyclopedia of Health and Aging: Sage 
publications; 2007:284-287.
2. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 
2011 expert consensus document on hypertension 
in the elderly: a report of the American College 
of Cardiology Foundation Task Force on Clinical 
Expert Consensus Documents. Circulation. 
2011;123(21):2434-2506.
3. Franklin SS, Gustin Wt, Wong ND, et al. 
Hemodynamic patterns of age-related changes 
in blood pressure. The Framingham Heart Study. 
Circulation. 1997;96(1):308-315.
4. Kearney PM, Whelton M, Reynolds K, 
Muntner P, Whelton PK, He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 
2005;365(9455):217-223.
5. Wolf-Maier K, Cooper RS, Banegas JR, et al. 
Hypertension prevalence and blood pressure levels 
in 6 European countries, Canada, and the United 
States. JAMA. 2003;289(18):2363-2369.
6. Blokstra A, van Dis I, Verschuren M. Prevalentie 
en trends van cholesterol, bloeddruk en gewicht 
in de Nederlandse bevolking. In: Koopman C, van 
Dis I, Visseren FLJ, Vaartjes I, Bots ML, eds. Hart- 
en vaatziekten in Nederland 2012. Den Haag: 
Hartstichting; 2012.
7. Vasan RS, Beiser A, Seshadri S, et al. Residual 
lifetime risk for developing hypertension in middle-
aged women and men: The Framingham Heart 
Study. JAMA. 2002;287(8):1003-1010.
8. Chobanian AV, Bakris GL, Black HR, et al. The 
Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure: the JNC 7 report. JAMA. 
2003;289(19):2560-2572.
9. Mancia G, De Backer G, Dominiczak A, et al. 
2007 Guidelines for the Management of Arterial 
Hypertension: The Task Force for the Management 
of Arterial Hypertension of the European Society 
of Hypertension (ESH) and of the European Society 
of Cardiology (ESC). J Hypertens. 2007;25(6):1105-
1187.
10. Conroy RM, Pyorala K, Fitzgerald AP, et al. 
Estimation of ten-year risk of fatal cardiovascular 
disease in Europe: the SCORE project. Eur Heart J. 
2003;24(11):987-1003.
11. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for 
ischaemic and intracerebral haemorrhagic stroke 
in 22 countries (the INTERSTROKE study): a case-
control study. Lancet. 2010;376(9735):112-123.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins 
R. Age-specific relevance of usual blood pressure 
to vascular mortality: a meta-analysis of individual 
data for one million adults in 61 prospective 
studies. Lancet. 2002;360(9349):1903-1913.
13. Lloyd-Jones DM, Larson MG, Leip EP, et al. 
Lifetime risk for developing congestive heart 
failure: the Framingham Heart Study. Circulation. 
2002;106(24):3068-3072.
14. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. 
The progression from hypertension to congestive 
heart failure. JAMA. 1996;275(20):1557-1562.
15. Velagaleti RS, Vasan RS. Heart failure in the 
twenty-first century: is it a coronary artery 
disease or hypertension problem? Cardiol Clin. 
2007;25(4):487-495.
16. Vasan RS, Levy D. The role of hypertension in the 
pathogenesis of heart failure. A clinical mechanistic 
overview. Arch Intern Med. 1996;156(16):1789-
1796.
17. Czernichow S, Zanchetti A, Turnbull F, et al. The 
effects of blood pressure reduction and of different 
blood pressure-lowering regimens on major 
cardiovascular events according to baseline blood 
pressure: meta-analysis of randomized trials. J 
Hypertens. 2011;29(1):4-16.
18. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, 
Lloyd-Jones DM. Impact of blood pressure and 
blood pressure change during middle age on the 
remaining lifetime risk for cardiovascular disease: 
the cardiovascular lifetime risk pooling project. 
Circulation. 2012;125(1):37-44.
19. Staessen JA, Gasowski J, Wang JG, et al. Risks 
of untreated and treated isolated systolic 
hypertension in the elderly: meta-analysis of 
outcome trials. Lancet. 2000;355(9207):865-872.
20. Dutch Institute of Healthcare Improvement 
(CBO), Dutch College of General Practitioners. 
Multidisciplinary guideline for cardiovascular 
risk management. Huisarts en wetenschap. 
2012;55(1):14-28.
21. Wolf-Maier K, Cooper RS, Kramer H, et al. 
Hypertension treatment and control in five 




22. Llisterri JL, Rodriguez-Roca GC, Escobar C, et al. 
Treatment and blood pressure control in Spain 
during 2002-2010. J Hypertens. 2012.
23. Paulsen MS, Andersen M, Thomsen JL, et al. 
Multimorbidity and blood pressure control in 
37651 hypertensive patients from Danish general 
practice. J Am Heart Assoc. 2013;2(1):e004531.
24. Biskupiak JE, Kim J, Phatak H, Wu D. Prevalence of 
high-risk cardiovascular conditions and the status 
of hypertension management among hypertensive 
adults 65 years and older in the United States: 
analysis of a primary care electronic medical 
records database. J Clin Hypertens (Greenwich). 
2010;12(12):935-944.
25. Calhoun DA, Jones D, Textor S, et al. Resistant 
hypertension: diagnosis, evaluation, and 
treatment. A scientific statement from the 
American Heart Association Professional Education 
Committee of the Council for High Blood Pressure 
Research. Hypertension. 2008;51(6):1403-1419.
26. Carrington MJ, Jennings GL, Stewart S. Pressure 
points in primary care: blood pressure and 
management of hypertension in 532 050 patients 
from 2005 to 2010. J Hypertens. 2013;31(6):1265-
1271.
27. World Health Organisation. A global brief on 
hypertension. 2013.
28. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/
AHA guideline for assessment of cardiovascular risk 
in asymptomatic adults: a report of the American 
College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. 
Circulation. 2010;122(25):e584-636.
29. van Dis I, Geleijnse JM, Verschuren WM, Kromhout 
D. Cardiovascular risk management of hypertension 
and hypercholesterolaemia in the Netherlands: 
from unifactorial to multifactorial approach. Neth 
Heart J. 2012;20(7-8):320-325.
30. Mancia G. Role of outcome trials in providing 
information on antihypertensive treatment: 
importance and limitations. Am J Hypertens. 
2006;19(1):1-7.
31. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. 
Cardiovascular protection using beta-blockers: a 
critical review of the evidence. J Am Coll Cardiol. 
2007;50(7):563-572.
32. Meredith PA, Ostergren J. From hypertension to 
heart failure -- are there better primary prevention 
strategies? J Renin Angiotensin Aldosterone Syst. 
2006;7(2):64-73.
33. Ammar KA, Jacobsen SJ, Mahoney DW, et al. 
Prevalence and prognostic significance of heart 
failure stages: application of the American 
College of Cardiology/American Heart Association 
heart failure staging criteria in the community. 
Circulation. 2007;115(12):1563-1570.
34. Barrios V, Escobar C, Sierra AD, Llisterri JL, Gonzalez-
Segura D. Detection of unrecognized clinical heart 
failure in elderly hypertensive women attended in 
primary care setting. Blood Press. 2010;19(5):301-
307.
35. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused 
update incorporated into the ACC/AHA 2005 
Guidelines for the Diagnosis and Management of 
Heart Failure in Adults A Report of the American 
College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines 
Developed in Collaboration With the International 
Society for Heart and Lung Transplantation. J Am 
Coll Cardiol. 2009;53(15):e1-e90.
36. Schocken DD, Benjamin EJ, Fonarow GC, et al. 
Prevention of heart failure: a scientific statement 
from the American Heart Association Councils on 
Epidemiology and Prevention, Clinical Cardiology, 
Cardiovascular Nursing, and High Blood Pressure 
Research; Quality of Care and Outcomes 
Research Interdisciplinary Working Group; and 
Functional Genomics and Translational Biology 
Interdisciplinary Working Group. Circulation. 
2008;117(19):2544-2565.
37. Baker DW, Bahler RC, Finkelhor RS, Lauer MS. 
Screening for left ventricular systolic dysfunction 
among patients with risk factors for heart failure. 
Am Heart J. 2003;146(4):736-740.
38. Bauml MA, Underwood DA. Left ventricular 
hypertrophy: an overlooked cardiovascular risk 
factor. Cleve Clin J Med. 2010;77(6):381-387.
39. Chang SM, Hakeem A, Nagueh SF. Predicting 
clinically unrecognized coronary artery disease: use 
of two- dimensional echocardiography. Cardiovasc 
Ultrasound. 2009;7:10.
40. Davies M, Hobbs F, Davis R, et al. Prevalence of 
left-ventricular systolic dysfunction and heart 
failure in the Echocardiographic Heart of England 
Screening study: a population based study. Lancet. 
2001;358(9280):439-444.
41. McMurray JJ, Adamopoulos S, Anker SD, et al. 
ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure 2012: The Task 
Force for the Diagnosis and Treatment of Acute and 




of Cardiology. Developed in collaboration with the 
Heart Failure Association (HFA) of the ESC. Eur 
Heart J. 2012;33(14):1787-1847.
42. Dahlstrom U, Hakansson J, Swedberg K, 
Waldenstrom A. Adequacy of diagnosis and 
treatment of chronic heart failure in primary health 
care in Sweden. Eur J Heart Fail. 2009;11(1):92-98.
43. Hobbs FD, Korewicki J, Cleland JG, Eastaugh J, 
Freemantle N. The diagnosis of heart failure in 
European primary care: The IMPROVEMENT 
Programme survey of perception and practice. Eur 
J Heart Fail. 2005;7(5):768-779.
44. Fonseca C, Morais H, Mota T, et al. The diagnosis 
of heart failure in primary care: value of symptoms 
and signs. Eur J Heart Fail. 2004;6(6):795-800, 821-
792.
45. Bosworth HB, Steinhauser KE, Orr M, Lindquist 
JH, Grambow SC, Oddone EZ. Congestive heart 
failure patients’ perceptions of quality of life: the 
integration of physical and psychosocial factors. 
Aging Ment Health. 2004;8(1):83-91.
46. Ekman I, Cleland JG, Swedberg K, Charlesworth A, 
Metra M, Poole-Wilson PA. Symptoms in patients 
with heart failure are prognostic predictors: 
insights from COMET. J Card Fail. 2005;11(4):288-
292.
47. Fonseca C. Diagnosis of heart failure in primary 
care. Heart Fail Rev. 2006;11(2):95-107.
48. Denollet J. Type D personality. A potential risk 
factor refined. J Psychosom Res. 2000;49(4):255-
266.
49. Perk J, De Backer G, Gohlke H, et al. European 
Guidelines on cardiovascular disease prevention 
in clinical practice (version 2012). The Fifth Joint 
Task Force of the European Society of Cardiology 
and Other Societies on Cardiovascular Disease 
Prevention in Clinical Practice (constituted by 
representatives of nine societies and by invited 
experts). Developed with the special contribution 
of the European Association for Cardiovascular 
Prevention & Rehabilitation (EACPR). Eur Heart J. 
2012;33(13):1635-1701.
50. Abramson J, Berger A, Krumholz HM, Vaccarino V. 
Depression and risk of heart failure among older 
persons with isolated systolic hypertension. Arch 
Intern Med. 2001;161(14):1725-1730.
51. Nicholson A, Kuper H, Hemingway H. Depression 
as an aetiologic and prognostic factor in coronary 
heart disease: a meta-analysis of 6362 events 
among 146538 participants in 54 observational 
studies. Eur Heart J. 2006;27(23):2763-2774.
52. Roest AM, Martens EJ, de Jonge P, Denollet J. 
Anxiety and risk of incident coronary heart disease: 
a meta-analysis. J Am Coll Cardiol. 2010;56(1):38-
46.
53. Grande G, Romppel M, Barth J. Association between 
type D personality and prognosis in patients with 
cardiovascular diseases: a systematic review and 
meta-analysis. Ann Behav Med. 2012;43(3):299-
310.
54. Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression 
increases the risk of hypertension incidence: a 
meta-analysis of prospective cohort studies. J 
Hypertens. 2012;30(5):842-851.
55. Gentil L, Vasiliadis HM, Preville M, Bosse C, Berbiche 
D. Association between depressive and anxiety 
disorders and adherence to antihypertensive 
medication in community-living elderly adults. J 
Am Geriatr Soc. 2012;60(12):2297-2301.
56. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, 
Avorn J. Noncompliance with antihypertensive 
medications: the impact of depressive symptoms 
and psychosocial factors. J Gen Intern Med. 
2002;17(7):504-511.
57. Friedman R, Schwartz JE, Schnall PL, et al. 
Psychological variables in hypertension: 
relationship to casual or ambulatory blood 
pressure in men. Psychosom Med. 2001;63(1):19-
31.
58. Verbeek DE, van Riezen J, de Boer RA, van Melle 
JP, de Jonge P. A review on the putative association 
between beta-blockers and depression. Heart Fail 
Clin. 2011;7(1):89-99.
59. Kostis JBR, R.C. Central nervous system effect of 
B-adrenergic-blocking drugs: the role of ancillary 
properties. Circulation. 1987;75(1):204-212.
60. Battes LC, Pedersen SS, Oemrawsingh RM, 
et al. Beta blocker therapy is associated with 
reduced depressive symptoms 12 months post 
percutaneous coronary intervention. J Affect 
Disord. 2012;136(3):751-757.
61. Hoogwegt MT, Kupper N, Theuns DA, Jordaens L, 
Pedersen SS. Beta-blocker therapy is not associated 
with symptoms of depression and anxiety in 
patients receiving an implantable cardioverter-
defibrillator. Europace. 2012;14(1):74-80.
62. Luijendijk HJ, van den Berg JF, Hofman A, Tiemeier 
H, Stricker BH. beta-blockers and the risk of incident 
depression in the elderly. J Clin Psychopharmacol. 
2011;31(1):45-50.
24
63. van Melle JP, Verbeek DE, van den Berg MP, Ormel 
J, van der Linde MR, de Jonge P. Beta-blockers 
and depression after myocardial infarction: a 
multicenter prospective study. J Am Coll Cardiol. 
2006;48(11):2209-2214.
64. Gottdiener JS, Arnold AM, Aurigemma GP, et al. 
Predictors of congestive heart failure in the elderly: 
the Cardiovascular Health Study. J Am Coll Cardiol. 
2000;35(6):1628-1637.
65. Lang RM, Bierig M, Devereux RB, et al. 
Recommendations for chamber quantification. Eur 
J Echocardiogr. 2006;7(2):79-108.
66. Nagueh SF, Appleton CP, Gillebert TC, et al. 
Recommendations for the evaluation of left 
ventricular diastolic function by echocardiography. 
J Am Soc Echocardiogr. 2009;22(2):107-133.
67. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for 
the echocardiographic assessment of the right 
heart in adults: a report from the American Society 
of Echocardiography endorsed by the European 
Association of Echocardiography, a registered 
branch of the European Society of Cardiology, and 
the Canadian Society of Echocardiography. J Am 
Soc Echocardiogr. 2010;23(7):685-713.
68. Denollet J. DS14: standard assessment of negative 
affectivity, social inhibition, and Type D personality. 
Psychosom Med. 2005;67(1):89-97.
69. Emons WH, Meijer RR, Denollet J. Negative 
affectivity and social inhibition in cardiovascular 
disease: evaluating type-D personality and 
its assessment using item response theory. J 
Psychosom Res. 2007;63(1):27-39.
70. Kroenke K, Spitzer RL, Williams JB, Lowe B. The 
Patient Health Questionnaire Somatic, Anxiety, and 
Depressive Symptom Scales: a systematic review. 
Gen Hosp Psychiatry. 2010;32(4):345-359.
71. Phelan E, Williams B, Meeker K, et al. A study of the 
diagnostic accuracy of the PHQ-9 in primary care 
elderly. BMC Fam Pract. 2010;11:63.
72. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief 
measure for assessing generalized anxiety disorder: 
the GAD-7. Arch Intern Med. 2006;166(10):1092-
1097.
73. Kroenke K, Spitzer RL, Williams JB, Monahan 
PO, Lowe B. Anxiety disorders in primary care: 
prevalence, impairment, comorbidity, and 
detection. Ann Intern Med. 2007;146(5):317-325.
74. Spitzer RL, Williams JB, Kroenke K, et al. Utility of 
a new procedure for diagnosing mental disorders 
in primary care. The PRIME-MD 1000 study. JAMA. 
1994;272(22):1749-1756.
75. American Psychological Association. Diagnostic 
and Statistical Manual of Mental Disorders 4th 
Edition-Text Revision (DSM-IV-TR). Washington 
D.C.: American Psychiatric Press; 2000.
Chapter 2
Behandeling van Hypertensie 
bij Oudere Patiënten in de 
Huisartsenpraktijk Volgens de 
Huidige CVRM Richtlijn
Ringoir L, Widdershoven JWMG, Imholz BPM, Romeijnders AC,





Objective: To determine adherence to the Dutch guideline on cardiovascular risk 
management (CVRM) and the association between adherence to the guideline and cardiac 
dysfunction as established with echocardiography in elderly primary care patients with 
hypertension.
Design: Cross-sectional study in five general practices in the South-East of the Netherlands 
affiliated with the primary care organization PoZoB and participating in a CVRM program.
Method: Between June 2010 and January 2013, primary care hypertension patients aged 
between 60 and 85 years were included if they did not have known heart failure or were 
treated by a cardiologist. A total of 568 patients with no history of myocardial infarction 
and/or atrial fibrillation were included and underwent an echocardiogram.
Results: Of the 568 patients included in this study, 214 (38%) were not treated according 
to the guideline. In these patients, abnormalities on the echocardiogram were observed in 
37% versus 21% of patients who were treated according to the guideline (p<.001). Logistic 
regression analysis showed a significant and clinically relevant association between an 
abnormal echocardiogram and treatment not conform to the guideline in the unadjusted 
(OR=2.18, 95% CI: 1.50-3.18) and adjusted analyses (OR=2.13, 95% CI:1.54-3.47).
Conclusion: Primary care hypertension patients who were not treated according to the 
Dutch CVRM guideline had significantly more often an abnormal echocardiogram. Future 
research should focus on the consequences of (non)adherence to hypertension treatment 
guidelines and a possible integration of an echocardiogram in the routine program of CVRM.
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Samenvatting
Doel: Het vaststellen van de mate waarin de NHG/CBO richtlijn cardiovasculair 
risicomanagement (CVRM) wordt gevolgd en de samenhang tussen het volgen van de richtlijn 
en hartafwijkingen vastgesteld met een echocardiogram bij oudere hypertensiepatiënten in 
de huisartsenpraktijk.
Opzet: Cross-sectioneel onderzoek in vijf huisartsenpraktijken in Zuidoost-Brabant die 
binnen de zorggroep PoZoB betrokken zijn bij CVRM.
Methode: Tussen juni 2010 en januari 2013 werden eerstelijns hypertensiepatiënten, tussen 
60 en 85 jaar oud, zonder diagnose hartfalen en niet onder behandeling bij een cardioloog 
benaderd voor het onderzoek. In totaal werden 568 patiënten, zonder bekend hartinfarct 
in de voorgeschiedenis en/of atrium fibrilleren geïncludeerd waarbij een  echocardiogram 
werd afgenomen
Resultaten: Van de 568 geïncludeerde patiënten werden 214 (38%) niet volgens de richtlijn 
behandeld. In deze groep werd bij 37% afwijkingen op het echocardiogram gevonden versus 
21% in de groep die wel volgens de richtlijn werd behandeld (p <.001). Logistische regressie 
liet een significante en klinisch relevante samenhang zien tussen behandeling niet volgens 
de richtlijn en afwijkingen op het echocardiogram in de ongecorrigeerde (OR=2.18, 95% CI: 
1.50-3.18) en in gecorrigeerde analyses (OR=2.13, 95% CI:1.54-3.47).
Conclusie: Eerstelijns hypertensiepatiënten die niet volgens de richtlijn CVRM behandeld 
werden hadden significant vaker afwijkingen op het echocardiogram. Toekomstig onderzoek 
zou zich kunnen richten op de consequenties van het wel/niet volgen van hypertensie 




De Framingham studie heeft laten zien dat volwassenen van 55 jaar oud 90% kans hebben om 
hypertensie te ontwikkelen in hun leven.1 In Nederland loopt de prevalentie van hypertensie 
bij mannen en vrouwen op van respectievelijk 61% en 55% in de leeftijdscategorie 60-70 jaar, 
tot ongeveer 70% bij beiden tussen 70-80 jaar.2 Hypertensie is niet alleen een belangrijke 
risicofactor  voor het krijgen van een transient ischemic attack (TIA)/cerebrovasculair accident 
(CVA),3 maar ook voor verschillende hartafwijkingen die bijdragen aan de ontwikkeling van 
hartfalen.4 Behandeling van de bloeddruk leidt tot een daling van de incidentie van CVA’s, 
coronaire events en hartfalen.5 
Sinds 2006 bestaat de multidisciplinaire richtlijn cardiovasculair risicomanagement (CVRM) 
van het Kwaliteitsinstituut voor de Gezondheidszorg (CBO) en het Nederlandse Huisartsen 
Genootschap (NHG) waarin de behandeling van hypertensie een belangrijk onderdeel is. 
In 2011 is er een herziene versie verschenen, met daarin wijzigingen in het advies voor 
het voorschrijven van antihypertensiva. De richtlijn adviseert bij patiënten met hypertensie, 
met verhoogd cardiovasculair risico, een behandeling met antihypertensiva met als doel 
een systolische bloeddruk (SBD) onder de streefwaarde (SBD≤140 mmHg bij patiënten 
tot 80 jaar, SBD≤160 bij patiënten van 80 jaar en ouder, SBD≤130 mmHg bij patiënten 
met diabetes).6 Het bereiken van de streefwaarde bij patiënten met hypertensie is niet 
eenvoudig. Verschillende Europese studies rapporteerden een SBD onder de streefwaarde 
bij slechts 23% tot 38% van de patiënten.7,8 Een onderzoek in Nederland onder de algemene 
populatie in 2007 liet zien dat bij 42% van de deelnemende hypertensie patiënten de 
bloeddruk voldoende onder controle was.9
De huidige richtlijn adviseert te starten met een diureticum of een calciumantagonist, 
vervolgens kan een ACE-remmer of een angiotensinereceptorantagonist (ARB) worden 
toegevoegd. Ten slotte kan een diureticum worden gecombineerd met een calciumantagonist 
en ACE-remmer of ARB. In tegenstelling tot de vorige richtlijn, is er voor bètablokkers in 
de huidige richtlijn een bescheiden rol weggelegd en worden deze alleen geadviseerd 
bij het bestaan van cardiale aandoeningen, zoals een eerder doorgemaakt hartinfarct of 
ritmestoornissen.6 Tot op heden ontbreken in de Nederlandse populatie cijfers over de mate 
waarin deze richtlijn voor behandeling van hypertensie in de eerste lijn wordt gevolgd. 
Hypertensie is een belangrijke risicofactor voor het ontwikkelen van hartfalen. Echocardiografie 
wordt gezien als de gouden standaard voor het vaststellen van hartafwijkingen in relatie tot 
hartfalen.10,11 Een afwijkend echocardiogram bij hypertensiepatiënten boven 60 jaar is niet 
hetzelfde als hartfalen. Maar veel echocardiografische afwijkingen bij deze patiënten (zoals 
ventrikel hypertrofie, diastolische dysfunctie, verminderde ejectiefractie, kleplijden) zijn 
29
Behandeling van hypertensie volgens de huidige CVRM richtlijn
2
belangrijke risicofactoren voor het ontwikkelen van hartfalen.4 
In 2010 is de eerstelijns zorggroep PoZoB in Zuidoost Brabant van start gegaan met de 
implementatie van het zorgprogramma CVRM, waarvan de behandeling van hypertensie 
een belangrijk onderdeel uitmaakt. Inmiddels zijn er ongeveer 25.000 hypertensie patiënten 
in dit zorgprogramma geïncludeerd. De vraagstellingen van de huidige studie waren om te 
onderzoeken (1) in welke mate de richtlijn CVRM wordt gevolgd bij de behandeling van 
hypertensie in de eerste lijn en (2) de mogelijke relatie tussen het bestaan van klinisch 
relevante  afwijkingen op het echocardiogram en het wel/niet behandeld worden volgens 
de richtlijn CVRM.
Patiënten en methode
Tussen juni 2010 en januari 2013 werden in vijf verschillende huisartspraktijken patiënten 
tussen 60 en 85 jaar met een ‘International Classification of Primary Care’ code voor 
hypertensie (K86/K87) in hun medisch dossier benaderd voor dit cross-sectionele onderzoek. 
De volgende patiënten werden geëxcludeerd: reeds onder behandeling bij een cardioloog, 
ernstige psychiatrische problematiek (psychose, borderline), cognitieve beperkingen, 
terminale ziekte, onvoldoende kennis van de Nederlandse taal. 
De studie werd goedgekeurd door de medische ethische toetsingscommissie van het 
St.- Elisabeth ziekenhuis in Tilburg.
Procedure
Na het ontvangen van de informed consent werd een afspraak ingepland voor een 
interview in de eigen huisartsenpraktijk. Tijdens dit interview door een verpleegkundige 
of praktijkondersteuner werden gewicht en lengte gemeten en een aantal gevalideerde 
en gestandaardiseerde vragenlijsten afgenomen. Daarnaast werd de bloeddruk gemeten 
na ongeveer 20 en 40 minuten in zittende houding. De gemiddelde waarden van beide 
bloeddrukken werden gebruikt om de SBD waarde vast te stellen. Bij alle patiënten 
werd tijdens een tweede afspraak een elektrocardiogram (ECG)  en echocardiogram 
gemaakt in de eigen huisartsenpraktijk door een gespecialiseerde echocardiografist 
van het huisartsenlaboratorium in Eindhoven, ‘Diagnostiek voor U’ en beoordeeld door 
een cardioloog gespecialiseerd in echocardiografie. Er was sprake van een afwijkend 
echocardiogram (op basis van een protocol aangepast voor de eerstelijn, gebaseerd op de 
richtlijnen voor echocardiografie12,13 ) bij een verminderde linkerkamer ejectiefractie (<55%), 
linker ventrikel hypertrofie (matig/ernstig), vergroot linker atrium (linker atrium volume 
index>29 ml/m2), diastolische dysfunctie, en (voor de leeftijd) klinisch relevant kleplijden.
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Klinische variabelen verkregen uit het medisch dossier waren een eerder doorgemaakt 
hartinfarct, bestaan van perifeer vaatlijden, eerder doorgemaakt CVA of TIA, bestaan van 
chronisch obstructief longlijden (COPD)/astma, bestaan van diabetes type 2, het aantal 
jaren sinds de diagnose hypertensie en het medicatiegebruik. 
Statistische analyse
De statistische analyses werden uitgevoerd met behulp van het IBM Statistical Package for 
the Social Sciences versie 19.0. De kenmerken van de steekproef werden gestratificeerd 
naar wel/geen behandeling volgens de richtlijn. Verschillen tussen groepen op continue 
variabelen werden bekeken met behulp van Student’s t-toetsen, zo nodig werden Welch’s 
t-toetsen gebruikt. Bij het toetsen van verschillen tussen groepen op nominale variabelen 
werden Chi2 toetsen gebruikt. De associatie tussen behandeling wel/niet volgens de richtlijn 
en het hebben van afwijkingen op het echocardiogram werd getoetst met multiple logistische 
regressie analyse (Odds ratio [OR], 95% betrouwbaarheidsinterval [BI]) gecorrigeerd voor de 
confounders leeftijd, geslacht, opleiding, roken, alcohol consumptie, BMI, het bestaan van 
diabetes type 2, het aantal jaren sinds de diagnose hypertensie en SBD.
Resultaten
Van de 913 patiënten die benaderd werden voor deelname deden uiteindelijk 619 (68%) 
patiënten mee. Vervolgens werden er post-hoc 2 patiënten geëxcludeerd omdat zij bij een 
cardioloog onder behandeling waren op het moment van inclusie. Van 5 patiënten was er 
geen informatie beschikbaar over de bloeddruk, van 6 patiënten waren er geen gegevens 
over medicatiegebruik, ook zij werden geëxcludeerd. Het voorschrijfbeleid voor hypertensie 
is anders in geval een eerder hartinfarct en/of atriumfibrilleren, daarom werden 38 patiënten 
met een hartinfarct in hun voorgeschiedenis en/of atriumfibrilleren op het ECG geëxcludeerd 
van de analyse. De kenmerken van de 568 overgebleven patiënten zijn weergegeven in tabel 
1. In totaal werden 214 (38%) van de 568 patiënten niet behandeld volgens de richtlijn. 
Hiervan kregen 24 patiënten met langer dan één jaar de diagnose hypertensie (range=2-30 
jaar, gemiddelde=11 jaar, SD=9.7) én een SBD boven de streefwaarde, geen medicatie. 
Binnen de totale groep (n=568) kregen van de patiënten met 1 antihypertensivum 33 
patiënten een bètablokker, van de patiënten met 2 antihypertensiva kregen 68 patiënten 
een combinatie die niet in de richtlijn wordt geadviseerd (waarvan 61 een combinatie met 
een bètablokker), en van de patiënten met 3 of meer antihypertensiva kregen 84 patiënten 
een combinatie die niet in de richtlijn wordt geadviseerd (waarvan 77 een combinatie met 
een bètablokker).
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de huidige richtlijn 
(n=354, 62%)
Niet behandeld volgens 




Man 243 (43%) 150 (42%) 93 (44%) .800
Leeftijd, gemiddelde (SD) 70 (6.5) 70 (6.4) 70 (6.7) .499
Partner 430 (76%) 268 (76%) 162 (76%) .999
Laag opgeleida 71 (13%) 45 (13%) 26 (12%) .844
Risicofactoren
Roken 78 (14%) 49 (14%) 29 (14%) .922
Alcohol consumptie ≥ 2 glazen per 
dag (gemiddeld)
176 (31%) 114 (32%) 62 (29%) .420
BMI kg/m², gemiddelde (SD) 28 (4.3) 28 (4.4) 28 (4.1) .562
SBD boven de streefwaardeb 378 (67%) 230 (65%) 148 (69%) .305
Klinisch relevant afwijkend ECG 
(n=580)
81 (14%) 47 (13%) 34 (16%) .388
Afwijkingen op het 
echocardiogram
155 (27%) 75 (21%) 80 (37%) <.001
Medische voorgeschiedenis
Aantal jaren sinds diagnose 
hypertensie, gemiddelde (SD)
12 (11) 11 (10.3) 14 (11.6) .002
Perifeer vaatlijden 20 (4%) 11 (3%) 9 (4%) .491
Eerder doorgemaakt TIA/CVA 47 (8%) 30 (9%) 17 (8%) .824
Diabetes type 2 63 (11%) 38 (11%) 25 (12%) .727
a. Laag opgeleid; minder dan middelbare school
b. Streefwaarde SBD ≤130 mmHg voor patiënten met diabetes type 2, ≤140 voor patiënten onder de 80 jaar, ≤160 
voor patiënten van 80 jaar en ouder
BMI, body mass index; SBD, systolische bloeddruk; TIA, transient ischemic attack; CVA, cerebrovasculair accident; 
ECG, electrocardiogram
In totaal hadden 378 patiënten (67%) een SBD boven de streefwaarden zoals gedefinieerd 
in de CVRM richtlijn.6 Tussen de groepen wel/niet behandeld volgens de richtlijn vonden 
we significante verschillen in afwijkingen op het echocardiogram (21% versus 37%, p<.001, 
figuur 1), en in het gemiddelde aantal jaren sinds de diagnose hypertensie (11 versus 14 jaar, 
p=.002, tabel 1). In de enkelvoudige logistische regressie was er een significante samenhang 
tussen afwijkingen op het echocardiogram en hogere leeftijd (OR=1.06, 95% BI:1.03-1.09), 
hogere SBD (OR=1.02, 95% BI:1.01-1.03) en behandeling niet volgens de richtlijn (OR=2.22, 
95% BI:1.52-3.24). In de gecorrigeerde regressie analyse was er een onafhankelijke en 
significante samenhang tussen een afwijkend echocardiogram en behandeling niet volgens 
de richtlijn (OR=2.31, 95% BI:1.54-3.47), evenals met hogere leeftijd (OR=1.05, 95% BI:1.02-
1.09) en hogere SBD (OR=1.02, 95% BI:1.01-1.03, tabel 2). 
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Figuur 1. Behandeling wel/niet volgens de huidige CVRM richtlijn opgesplitst naar wel/geen afwijkingen op het 
echocardiogram bij 568 patiënten met hypertensie tussen 60-85 jaar die behandeld worden in de eerstelijn. 
(Pearson Chi2=17.6, df =1, p<.001).
 Afwijkingen; linker ventrikel ejectie fractie<55%, linker ventrikel hypertrofie, diastolische dysfunctie, vergroot linker
atrium, wandbewegingsstoornissen, aorta-, mitralis-, of tricuspidalisklepafwijkingen, rechter ventrikel hypertrofie
Tabel 2. (On-)gecorrigeerde odds ratio’s voor de associatie tussen behandeling niet volgens de richtlijn 
(onafhankelijke variabele) en afwijkingen op het echocardiogram (afhankelijke variabele) bij 568 patiënten met 
hypertensie tussen 60-85 jaar die behandeld worden in de eerstelijn.
Ongecorrigeerde odds ratio’s OR 95% Betrouwbaarheidsinterval
Leeftijd 1.06 1.03-1.09
Geslacht (vrouw) 1.05 .72-1.52
Laag opgeleida .89 .51-1.58
Roken .60 .33-1.08
Alcohol consumptie ≥ 2 glazen per dag .84 .56-1.27
BMI .97 .93-1.02
Bestaan van diabetes type 2 1.07 .60-1.92
Aantal jaren sinds diagnose hypertensie 1.00 .98-1.02
SBD in mmHg 1.02 1.01-1.03
Behandeling niet volgens de huidige richtlijn 2.18 1.50-3.18
Gecorrigeerde odds ratio’s
Leeftijd 1.05 1.02-1.09
Geslacht (vrouw) 1.16 .76-1.77
Laag opgeleid .67 .35-1.28
Roken .57 .30-1.10
Alcohol consumptie ≥ 2 glazen per dag .80 .50-1.26
BMI .96 .91-1.01
Bestaan van diabetes type 2 1.17 .63-2.19
Aantal jaren sinds diagnose hypertensie .99 .97-1.00
SBD in mmHg 1.02 1.01-1.03
Behandeling niet volgens de huidige richtlijn 2.31 1.54-3.47
a. Laag opgeleid, minder dan middelbare school
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Discussie
De resultaten van dit onderzoek laten zien dat 38% van een steekproef van 568 
hypertensiepatiënten uit het zorgprogramma CVRM van PoZoB niet wordt behandeld volgens 
de huidige richtlijn CVRM. Deze 38% bestaat grotendeels uit patiënten die een bètablokker 
krijgen voorgeschreven al dan niet in combinatie met een ander antihypertensivum (n=171), 
zonder dat er sprake is van een hartinfarct in de voorgeschiedenis of hartfalen. Daarnaast is 
er een kleine groep patiënten die geen antihypertensiva krijgt voorgeschreven maar wel een 
SBD hebben boven de streefwaarde (n=29). De patiënten die niet volgens de richtlijn CVRM 
worden behandeld hebben vaker afwijkingen op een echocardiogram dan de patiënten die 
wel volgens de richtlijn behandeld worden (37% vs. 21%, p<.001). Deze samenhang blijft 
significant na correctie voor confounders zoals leeftijd, jaren sinds diagnose van hypertensie, 
en de hoogte van de SBD.
Ondanks de aanwezigheid van richtlijnen en het bestaan van een groot aantal 
antihypertensiva is de praktijk vaak weerbarstig.  Niet alleen werd de richtlijn bij 38% niet 
gevolgd, een SBD onder de streefwaarde werd slechts bij 33% van de patiënten gemeten. 
Dit komt overeen met resultaten uit andere Europese studies, waar bij maximaal 38% 
van de hypertensiepatiënten een bloeddruk onder de streefwaarde werd gevonden.7,8 
Een terughoudend voorschrijfbeleid door huisartsen is een mogelijke oorzaak voor deze 
lage cijfers; zo is bij ouderen het gebruik van antihypertensiva een bekende oorzaak van 
vallen door orthostatische hypotensie.14 Patiënten die niet volgens de richtlijn behandeld 
werden hadden echter wel vaker afwijkingen op het echocardiogram. Bij 24 patiënten die 
geen antihypertensiva kregen voorgeschreven was de gemiddelde duur sinds de diagnose 
hypertensie maar liefst 11 jaar. Men kan zich afvragen of zoveel jaar na het stellen van de 
diagnose hypertensie een afwachtend beleid nog is te verdedigen, zeker gelet op de leeftijd 
(gemiddeld 70 jaar). Daarnaast kreeg het overgrote gedeelte van de patiënten die niet volgens 
de richtlijn behandeld werden een (combinatie met een) bètablokker voorgeschreven. 
Uit eerder onderzoek blijkt dat het gebruik van bètablokkers als monotherapie of eerste 
keus antihypertensivum minder effectief is in het verminderen van cardiovasculair risico 
(waaronder de incidentie van een beroerte en cardiovasculaire sterfte).15 Bovendien is 
de therapietrouw bij het gebruik van bètablokkers lager omdat deze meer bijwerkingen 
geven.15 Het feit dat bijna 40% van de patiënten niet volgens de richtlijn werd behandeld 
moet bezien worden in het licht van een inclusie van ongeveer 25% van de deelnemers 
voordat de herziene richtlijn CVRM werd uitgebracht. Dit kan echter slechts gedeeltelijk het 
niet opvolgen van de nieuwe richtlijn verklaren. 
Een klinisch relevant afwijkend echocardiogram is niet hetzelfde als het hebben van 
hartfalen. Echter, de literatuur is zeer eenduidig als het gaat om de voorspellende waarde 
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van een afwijkend echocardiogram op het ontwikkelen later van hartfalen.16-20 Op basis van 
het afwijkend echocardiogram werden door een onafhankelijk cardioloog (van buiten de 
regio) adviezen gegeven aan de huisarts. Deze bestonden bij 50% van de afwijkingen uit een 
eenvoudig medicatieadvies (voornamelijk ophogen van de gebruikte dosis, of toevoegen 
van een ACE-remmer of ARB aan bestaande medicatie). 
Dit onderzoek kent een aantal beperkingen. Allereerst is dit een cross-sectioneel onderzoek, 
waardoor het doen van causale uitspraken niet mogelijk is. Prospectief onderzoek moet 
aantonen of het volgen van de richtlijn CVRM ook effect heeft op harde eindpunten zoals 
cerebrovasculaire events, cardiovasculaire ziekte (ontwikkelen van hartfalen) en sterfte. 
Omdat de huidige studie plaatsvond binnen het CVRM zorgprogramma van PoZoB - hetgeen 
in analogie met het eerstelijns diabetes programma in principe ‘’levenslange’’ follow-up 
impliceert - is het eenvoudig om over 5 jaar bij de participanten (al dan niet selectief) het 
echocardiogram te herhalen. Op deze manier is voor een eerstelijns hypertensie populatie 
de voorspellende waarde van een afwijkend echocardiogram op het ontwikkelen van klinisch 
relevant hartfalen eenvoudig te bepalen. 
Het zou mogelijk kunnen zijn dat een geselecteerde groep participeerde in het onderzoek, 
maar er was een hoge respons voor participatie in deze studie (68%). Bovendien bleek de 
man/vrouw verdeling opgesplitst naar leeftijdscategorieën goed overeen te komen met 
de totale hypertensie CVRM populatie van  PoZoB. Dit suggereert dat de cijfers van de 
huidige steekproef representatief zijn voor de gehele hypertensie populatie in de leeftijd 
tussen 60 en 85 jaar binnen het CVRM programma van PoZoB. Indien bij 1/3 een afwijkend 
echocardiogram zou worden gevonden waarbij bij 50% een eenvoudig medicatie advies 
volstaat zou het toevoegen van een echocardiogram aan het CVRM protocol mogelijk te 
overwegen zijn. Het echocardiogram is goedkoop (75 euro), kan door huisartsen worden 
aangevraagd en in principe in de huisartsenpraktijk plaatsvinden. Toekomstig onderzoek in 
de eerstelijn zal de kosteneffectiviteit van het standaard invoeren van een periodiek uit te 
voeren echocardiogram bij hypertensie patiënten boven de 60 jaar in kaart moeten brengen.
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Background: Hypertension is very prevalent and an important risk factor for heart failure. This 
study aimed to determine the prevalence of cardiac abnormalities on an echocardiogram, in 
association with systolic blood pressure >160 mmHg, and relevance of screening in elderly 
primary care hypertension patients.
Methods: 596 primary care hypertension patients aged between 60-85 years, without 
known heart failure, not currently treated by a cardiologist, were included in this cross-
sectional study and underwent an echocardiogram and structured interview including blood 
pressure assessment between June 2010 and January 2013. 
Results: An abnormal echocardiogram was found in 30% (n=181) including: dilated left 
atrium (>29ml/m²) in 10% (n=62); reduced left ventricle ejection fraction (<55%) in 9% 
(n=51); left ventricle hypertrophy in 6% (n=38); and diastolic dysfunction in 6% (n=36) of the 
patients. These 4 categories included 133/181 abnormal echocardiograms. The remaining 
48 patients had miscellaneous conditions. 38% of the patients had a systolic blood pressure 
of 140-160 mmHg, and 29% had a systolic blood pressure of >160 mmHg. After adjustment 
for other risk factors, a systolic blood pressure of >160 mmHg (apart from age, OR:1.07, 95% 
CI:1.03-1.10) was independently related to an abnormal echocardiogram (OR:1.57, 95% 
CI:1.03-2.38). 
Conclusion: Screening of unselected primary care hypertension patients with an 
echocardiogram results in an unexpected high number (30%) of abnormal echocardiograms, 
prospective studies have shown these to be associated with poor cardiac outcomes. 
Furthermore 29% of patients had a systolic blood pressure of >160 mmHg. Screening of all 
elderly primary care hypertension patients should be considered. 
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Introduction 
Hypertension is a highly prevalent condition, the Framingham study described a lifetime 
risk for developing hypertension of 90% in people with a normal blood pressure at age 
55.1 Hypertension can result in coronary artery disease and changes in ventricular 
function and structure, and is a major risk factor for developing heart failure.2 Recent 
heart failure guidelines indicate that early diagnosis and treatment of heart failure are 
paramount for reducing morbidity and mortality.3 The American guidelines for assessment 
of cardiovascular risk in asymptomatic adults suggest that echocardiography to detect left 
ventricle hypertrophy (LVH) should be considered in adults with hypertension.4 In 2011, the 
American Heart Association (AHA) published a document on Hypertension in the Elderly in 
which they advocated to assess an echocardiogram in a sub-group of elderly.2  
In primary care, treatment of hypertension as part of cardiovascular risk management has 
become a major issue. A primary care study in patient with hypertension showed that more 
severe hypertension is associated with a higher risk of cardiovascular events.5 However, 
achieving optimal blood pressure control in hypertension patients is difficult,6 with even 
poorer results with increasing age.7 Symptomatic heart failure is generally preceded by 
asymptomatic cardiac dysfunction or changes in cardiac structure.8  In a previous study in 
elderly hypertensive women, LVH was a main factor associated with unrecognized heart 
failure, especially in those with less than optimal blood pressure control.9 Appropriate 
treatment with medication can prevent or delay the onset of symptoms of heart failure 
and also reduce mortality.10 Also valvular heart disease and wall motion abnormalities can 
be major causes of heart failure and are related to coronary artery disease.11 The current 
European guidelines for diagnosis and treatment of acute and chronic heart failure state 
that echocardiography is one of the most useful tests, which can be used to assess left and 
right ventricular systolic and diastolic function, wall motion, wall thickness, and valvular 
function.3 Until now, no data are available on the prevalence of abnormal cardiac outcomes 
in primary care hypertension patients with no established cardiac disease. Although 
echocardiography is nowadays a cheap and non-invasive assessment with high sensitivity to 
detect cardiac abnormalities, it is not commonly used in primary care.12 
In the present study, a sample of elderly primary care patients with hypertension was 
screened with the aid of echocardiography, using a protocol suitable for the assessment of 
cardiac abnormalities in a primary care setting. The objectives of the current study were to 
examine (1) the prevalence of an abnormal echocardiogram in elderly hypertension patients 
in primary care, (2) the number of patients with appropriately regulated blood pressure, 
and (3) the relation between the blood pressure and an abnormal echocardiogram, after 




Study design and patient population
Between June 2010 and January 2013, primary care patients aged between 60-85 years with 
an International Classification of Primary Care for hypertension (K86/K87) in their medical 
record, were recruited from GPs affiliated with the primary care organization PoZoB. 
Patients were excluded in case of a previous diagnosis of heart failure and/or treatment 
by a cardiologist at the time of inclusion (patients with a previous myocardial infarction, 
not being followed by a cardiologist were included in the study); severe psychiatric illness 
other than mood or anxiety disorders; serious cognitive impairments; terminal cancer; 
insufficient knowledge of the Dutch language, or inability to read. This study complies with 
the Declaration of Helsinki and was approved by the Medical Ethics Board of the st.-Elisabeth 
Hospital in Tilburg, the Netherlands.
Study procedure and data collection
Eligible patients received information about the study both orally and in writing. In case 
of informed consent, an appointment for an interview was scheduled. During this first 
appointment with a health care nurse at their local GP’s office, eligible patients underwent 
a structured interview and physical examination. Blood pressure was measured after 
approximately 20 and 40 minutes of sitting. The mean value of both blood pressure 
measurements was used for data analysis. In addition, demographic and clinical variables 
were obtained during the interview and by reviewing the patient’s medical records. After 
the interview, a second appointment was planned for an echocardiogram, also at the local 
GP office. 
Assessment of the echocardiogram
The echocardiogram was carried out and evaluated by an experienced echocardiographist 
of the local Primary Care Laboratory “Diagnostiek voor U” in Eindhoven, The Netherlands. 
After assessment by the echocardiographist, all the echocardiograms were reviewed by 
a cardiologist specialized in echocardiography, who indicated if the echocardiogram was 
abnormal according to the criteria as shown in Table 1. 
Echocardiograms were made with the Philips CX 50 equipped with a cardiology package 
and an s5 transducer. Because the echocardiogram was made in the local general practices, 
a simplified protocol was used to assess cardiac abnormalities. Left ventricular ejection 
fraction (LVEF) was calculated using the Simpson formula in the apical four-chamber and 
apical two-chamber view.13 LVH was calculated with measurement of septal and posterial 
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wall thickness and LA volume index (LAVI) was calculated with LA volume/body surface 
area (ml/m2).13 Because in individuals aged >60 years without a history of cardiovascular 
disease an E/A ratio<1 and deceleration times of >200ms are common, diastolic dysfunction 
was considered when also LVH was present in case of grade I diastolic dysfunction.14 Right 
ventricle hypertrophy (RVH) was calculated with measurement of right ventricle subcostal 
wall thickness.15 Furthermore, aortic valve insufficiency, aortic valve stenosis, mitral valve 
insufficiency, mitral valve stenosis, mitral annulus calcification (MAC), tricuspid valve 
insufficiency, wall motion abnormalities, aortic dilatation, cardiomyopathy, and congenital 
abnormalities were assessed. The cut off points for abnormal findings in the abovementioned 
categories are described in Table 1. 








LVEF<55%13 51 (9%) 30 (11%) 21 (6%) .029
LVH; septal and posterior wall thickness≥13 mm (moderate/
severe13)
38 (6%) 23 (9%) 15 (5%) .037
LAVI>29 ml/m² 13 62 (10%) 20 (8%) 42 (13%) .044
Diastolic dysfunction ( E/A ratio<1 and DTs>200ms, and 
presence of LVH in case of grade I diastolic dysfunction)14
36 (6%) 14 (5%) 22 (7%) .501
RVH; subcostal wall thickness≥6mm  (mild/moderate/severe) 16 (3%) 7 (3%) 9 (3%) .964
Aortic valve insufficiency (moderate/severe, AI P1/2 time) 10 (2%) 3 (1%) 7 (2%) .359
Aortic valve stenosis (mean gradient≥30 mmHg) 6 (1%) 5 (2%) 1 (0.3%) n.a.
Mitral valve insufficiency (moderate/severe, ≥grade 2) 20 (3%) 6 (2%) 14 (4%) .190
MAC 11 (2%) 6 (2%) 5 (2%) .490
Tricuspid valve insufficiency (moderate/severe, ≥grade 2) 5 (1%) 0 5 (2%) n.a.
Wall motion abnormalities (hypokinesia, akinesia or 
dyskinesia)
26 (4%) 23 (9%) 3 (1%) <.001
Aortic dilatation>40mm  (moderate/severe) 4 (1%) 2 (0.8%) 2 (0.6%) n.a.
Cardiomyopathy (hypertrophic) 3 (0.5%) 1 (0.4%) 2 (0.6%) n.a.
Congenital abnormalities 2 (0.3%) 1 (0.4%) 1 (0.3%) n.a.
Total ≥1 abnormality 181 (30%) 84 (32%) 97 (29%) .493
LAVI, left atrium volume index; LVEF, left ventricular ejection fraction; LVH, left ventricle hypertrophy; MAC, mitral 
annulus calcification; RVH, right ventricle hypertrophy.
Statistical analyses
Statistical analyses were performed using the IBM Statistical Package for the Social Sciences 
version 18.0. Differences between men and women in baseline characteristics were assessed 
with Chi² tests or Student’s/Welch’s T-tests when appropriate. The different echocardiogram 
parameters were assessed in the group as a whole and for men and women separately, 
these differences were assessed with Chi² tests. Adjusted odds ratio’s were calculated using 
multiple logistic regression, with an abnormal echocardiogram (in which all abnormalities 
as described in Table 1 were taken together) as dependent variable. A possible relation 
42
Chapter 3
between an abnormal echocardiogram and systolic blood pressure (SBP) was adjusted for 




From 5 different GP-practices, 913 eligible patients with hypertension were approached 
and 619 (68%) patients agreed to participate. Of these 619 participants, 2 were excluded 
because they were already being treated by a cardiologist, 5 were excluded because the 
echocardiogram was not of sufficient quality and 16 patients did not have an echocardiogram, 
596 (65%) patients were included in the analysis. 
Baseline characteristics
Table 2 shows the baseline characteristics, the mean age of the study patients was 70.4+/-
6.5 years and the majority was female (56%,n=332). Men were more often higher educated 
and living together with a partner. Men were significantly more likely to have had a previous 
myocardial infarction, to consume more than 2 glasses alcohol a day on average, to have 
peripheral arterial disease, and to have higher diastolic blood pressure. Of the total sample, 
67% had a SBP>140 mmHg (71% males, 64% females, p=.100), and 29% had a SBP>160 mm 
Hg (31% males, 27% females, p=.213) (figure 1). Mean SBP was 150+/-19.6 mmHg.








































































































































































































































































































































































































































































































































































































Table 1 shows the echocardiographic findings. In total, 181 (30%) of the patients had one 
or more cardiac abnormalities on the echocardiogram (32% males, 29% females, p=.493). A 
dilated left atrium, defined by a left atrium volume index of >29 ml/m²,13 was most prevalent 
(10%), this was more prevalent in females than in males (13% vs. 8%, p=.044). While a left 
atrium>29 ml/m2 is described as abnormal,13 a left atrium of ≥34 ml/m2 can be an important 
independent predictor of death and heart failure.14 Therefore we also report the prevalence 
of LAVI ≥34 ml/m², which was present in 37 patients (6%) (data not shown in table). A 
diminished LVEF (<55%) was observed in 9% of the patients, which was more prevalent in 
males than in females (11% vs. 6%, p=.029). LVH was observed in 6% of the patients, which 
was significantly more prevalent in males than in females (9% vs. 5%, p=.037). Diastolic 
dysfunction was observed in 6% of the patients. These 4 categories described above 
consisted of 22% of the total study population. Wall motion abnormalities were seen in 4% 
of the patients, with a significantly higher prevalence in males (9% vs. 1%, p<.001). When 
excluding patients with a previous MI, (n=28, n=22 males, n=6 females), 29% of the patients 
(n=164/568) had an abnormal echocardiogram, the prevalence of abnormal cardiac echo 
did not differ between men and women (p=.690, data not shown). 
In table 3 the results of the multiple logistic regression analysis are shown with an abnormal 
echocardiogram as dependent variable and SBP as independent variable, after adjusting 
for age, gender, education, current smoking, alcohol consumption, BMI, and diastolic blood 
pressure. Higher age was significantly associated with abnormal echocardiogram (OR=1.07, 
95% CI=1.03-1.10), as well as a SBP>160 mmHg (OR=1.57, 95% CI=1.03-2.38). When this 
analysis was repeated without patients with a history of MI, higher age and SBP>160 mmHg 
remained significantly and independently associated with an abnormal echocardiogram 
(higher age, OR=1.06, 95% CI=1.03-1.10; SBP>160 mmHg, OR=1.64, 95% CI=1.07-2.52). 
Table 3. Multiple logistic regression, dependent variable: abnormal echocardiogram in 587 elderly primary care 
hypertension patients
Variable Odds ratio (95% CI) P-value
Female gender .88 (.60-1.28) .496
Age 1.07 (1.03-1.10) <.001
Low education .74 (.42-1.31) .298
Current smoking .58 (.31-1.06) .077
Regular alcohol use (≥ 2 glasses per day) .86 (.57-1.30) .466
BMI .99 (.94-1.03) .528
DBP>90 mmHg 1.02 (.62-1.65) .951
SBP>160 mmHg 1.57 (1.03-2.38) .034
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
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The results of this study show that 30% of the primary care hypertension patients in this 
study had an abnormal echocardiogram. A SBP >140 mmHg was observed in 67% of the 
patients, and 29% had a SBP >160 mmHg. A DBP >90 mmHg was observed in 20% of 
the patients. The most prevalent echocardiographic abnormalities were an enlarged left 
atrium, diminished LVEF, LVH, and diastolic dysfunction.  Higher age and elevated SBP 
(>160 mmHg) were independently related to an abnormal echocardiogram. After excluding 
the patients with a history of myocardial infarction, the percentage of patients with an 
abnormal echocardiogram remained high (29%), and age and SBP remained significantly 
and independently related to an abnormal echocardiogram.
Comparison with previous reports
The prevalence of an enlarged left atrium is similar to findings of a previous study in patients 
without known cardiac disease who were referred for echocardiography.16  In that study, an 
enlarged atrium (>29 ml/m2) was also present in 10% of the patients. Although the study 
population was on average approximately 10 years younger, these patients were selected 
for echocardiography because of hypertension as well as palpitations, suspected valve 
disease, dyspnea, or chest discomfort.16 It has previously been shown that an enlarged left 
atrium is a significant independent predictor of major adverse cardiac events.17 Reduction of 
left atrial diameter resulting from antihypertensive treatment is associated with reduction 
in LVH and reduced incidence of atrial fibrillation and or mitral regurgitation.18 A diminished 
LVEF in asymptomatic patients, which was found in 9% of the participants of the current 
study, is highly predictive for increased future cardiac morbidity and mortality.19 In addition, 
LVH is an important predictor of cardiovascular events, and adequate antihypertensive 
treatment is associated with a decrease in left ventricular mass as well as reduced rates 
of cardiovascular death, myocardial infarction and stroke.20 Diastolic dysfunction is also an 
independent predictor of cardiovascular events,21 treatment with ACE inhibitors or ARBs is 
recommended.22 Moreover, wall motion abnormalities in adults without clinically recognized 
cardiovascular disease are independently associated with future cardiovascular events.23 
In general, no differences were found between males and females in the presence of an 
abnormal echocardiogram. However, when looking at the abnormalities in more detail, 
males and females differed in the prevalence of LAVI, LVH, and wall motion abnormalities. 
The difference in wall motion abnormalities can be explained by the significantly higher 
number of men with a history of a myocardial infarction, which is in agreement with 
previous studies.23 Similar to our study, Katayama et al. showed a significantly higher LAVI 
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in women as compared to men in a sample of adults with normal ejection fraction.24 In a 
review of echocardiographic studies on LVH in hypertensive patients, LVH was found in a high 
percentage of hypertensive patients (pooled range between 36%-41%), and no significant 
differences were found between men and women.25 However, these patients were mostly 
selected and the prevalence varied widely, partly depending on the criteria used to diagnose 
LVH.25 Comparable to several other studies,6-8 blood pressure control in this study (SBP≤140 
mmHg) was rather poor. The findings in the current study are comparable to a Finnish 
primary care study in which 35% of the hypertension patients had a SBP of ≤140 mmHg.26 
A Swiss primary care study showed that optimal blood pressure control was achieved in 
approximately 54%, which implies that higher numbers of optimal blood pressure control 
can be attainable.27  
Strengths and limitations of the study
A major strength of this study was the focus on relatively healthy primary care patients, 
where preventive measures to reduce cardiac events are of importance. Furthermore, to 
our knowledge this study is the first to provide a clear overview of prevalence and associates 
of cardiac dysfunction on an echocardiogram in unselected elderly hypertension patients in 
primary care. Since hypertension is an important risk factor for cardiac disease, the results 
of screening on possibly modifiable cardiac abnormalities in a primary care population with 
hypertension with an echocardiogram are very relevant for cardiovascular risk management 
and prevention. The course of the abnormalities may be favorably altered with adequate 
treatment, resulting in prevention of heart failure and other cardiac disease.5,28 In addition, 
echocardiography is easily accessible, cheap, and an acceptable and simple method for 
screening patients in general.2,4 
Some limitations of the study should be mentioned. First, the results may not be generalized 
to other settings than primary care. However, most of the hypertension patients are 
preferentially seen in primary care, the results of this study are relevant for a large group 
of hypertension patients. Since the Framingham study showed that 90% of people aged 55 
years without elevated blood pressure will eventually develop hypertension,1 hypertension 
patients represent a large group. Second, we used a simplified protocol to define cardiac 
abnormalities on the echocardiogram. Since the echocardiograms were all performed in the 
local general practices, a simpler screening echocardiogram was suitable. In case of need for 
further detailed assessment of cardiac dysfunction, patients were referred to a cardiologist 
in a hospital. Third, this is a cross-sectional study, which limits the possibility to report the 
impact of the cardiac abnormalities found in this screening on future cardiovascular events. 
However, other prospective studies already have indicated the association of the specific 
abnormal echocardiograms also found in the current study and the development of future 
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cardiovascular events such as atrial fibrillation and cardiovascular death.18-21,23,29 Although 
the echocardiogram is cheap, and easy to perform at the GP office, the cross-sectional 
design does not allow for an adequate cost-effectiveness analysis. However, given the fact 
that most of the abnormal echocardiograms could be accompanied by a simple medication 
change advice to the GP (higher dose or change to other regimens were given in 48% of 
the patients with an abnormal echocardiogram, 15% of the total study population) which 
has been shown to improve future cardiovascular health, the findings in the current cross-
sectional study seem promising with regard to cost-effectiveness.
Clinical implications
In the current study, most of the adapted World Health Organization criteria of screening 
of Wilson and Jungner are met.30 Hypertension is a highly prevalent condition, the 
screening instrument is cheap and non-invasive, user friendly offered at the primary care 
office. Moreover, interventions are available (change of medication regimens) which have 
repeatedly been shown in prospective follow-up studies to markedly improve cardiovascular 
outcomes.18,20,22 An abnormal echocardiogram is a major risk factor to develop heart failure 
with poor prognostic outcome.17,19-21 Up to 2/3 of the primary care hypertension patients do 
not meet optimal blood pressure cut-offs suggesting that there is still a way to go in primary 
care cardiovascular risk management, especially because high SBP was independently 
related to an abnormal echocardiogram. 
Conclusions
This study detected an unexpectedly high prevalence of abnormal echocardiograms in 
unselected elderly primary care hypertension patients. Previous research has shown that 
these cardiac abnormalities are associated with poor cardiac outcomes, and adequate 
treatment can improve prognosis. Screening of all elderly hypertension patients by means 
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Symptoms Associated with 
an Abnormal Echocardiogram 
in Elderly Primary Care 
Hypertension Patients
Ringoir L, Widdershoven JWMG, Pedersen SS, Romeijnders AC, Keyzer JML, Pop VJM




Background: The prevalence and diagnostic value of heart failure symptoms in elderly 
primary care patients with hypertension is unknown.
Aim: To assess the prevalence, sensitivity, specificity, positive, and negative predictive value 
of symptoms in association with an abnormal echocardiogram.
Design and setting: Cross-sectional screening study in five general practices in the South-
East of The Netherlands.
Method:  Between June 2010 and January 2013, 591 primary care hypertension patients 
aged between 60 and 85 years were included, without known heart failure and not treated 
by a cardiologist. All patients underwent an echocardiogram and a structured interview 
including assessment of heart failure symptoms; shortness of breath, fatigue, oedema, cold 
extremities, and restless sleep.
Results and conclusion: Restless sleep was reported by 25%, cold extremities by 23%, fatigue 
by 19%, shortness of breath by 17%,  and oedema by 13%. Oedema was the only symptom 
significantly associated with an abnormal echocardiogram (positive predictive value was 
45%, sensitivity 20%, and specificity 90%, OR 2.12; 95% CI=1.23-3.64), apart from higher age 
(OR 1.06; 95% CI=1.03-1.09), previous myocardial infarction (OR 3.00; 95% CI=1.28-7.03), 
and a systolic blood pressure of >160 mmHg (OR 1.62; 95% CI=1.08-2.41). Screening with 
echocardiography might be considered in patients with oedema.
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Introduction 
Hypertension is highly prevalent, with the Framingham study showing a lifetime risk for 
developing hypertension of 90% in people with a normal blood pressure at age 55.1 A high 
blood pressure can result in coronary artery disease and changes in ventricular function and 
structure,2 and is a major risk factor for incident heart failure,3 with a five-year survival rate of 
35% according to previous research.4 Early diagnosis and treatment of heart failure are crucial 
for reducing heart failure related morbidity and mortality.5-7 General practitioners (GPs) are 
most frequently involved in the diagnosis of heart failure.8 More severe hypertension in 
primary care patients is associated with a higher risk of cardiovascular events,9 and lowering 
blood pressure can reduce risk of major cardiovascular events.10 However, in less than 50% 
of patients above the age of 65 hypertension is properly managed.11-13 Therefore, elderly 
hypertension patients, especially those with less than optimal blood pressure, are at high 
risk for heart failure. 
Several important patient-reported symptoms of heart failure are oedema, dyspnea, and 
fatigue.14-16 Because most patients with possible heart failure will present themselves first in 
primary care,16 it is important for a GP or practice nurse (PN) to identify symptoms predictive 
of this condition. However, most studies on symptoms used for assessment of heart failure 
have focused on hospital populations8 and/or on patients who presented themselves with 
dyspnea,17,18 or had suspected heart failure.19 Furthermore, the majority of studies evaluated 
symptoms only in association with left ventricular systolic dysfunction and did not take other 
relevant abnormalities such as diastolic function into account.5,8 Left ventricular hypertrophy 
(LVH), an enlarged left atrium, valvular heart disease, and wall motion abnormalities can 
also be major causes of heart failure and are related to coronary artery disease.20-22 
Echocardiography is seen as the gold standard for the diagnosis or confirmation of cardiac 
dysfunction associated with heart failure5 and can be used to detect cardiac abnormalities.2 
Although the diagnostic value of symptoms and signs of heart failure has been topic of 
debate17, attention to symptoms can still be of relevance in patients at risk for heart failure.5 
Until now it is unclear in elderly primary care hypertension patients which heart failure 
symptoms may be associated with an abnormal echocardiogram. The objectives of the 
current study were to examine (1) the prevalence of symptoms which are in general related to 
cardiac dysfunction reflected by an abnormal echocardiogram, (2) the sensitivity, specificity, 
positive, and negative predictive value of symptoms of an abnormal echocardiogram, and 





Study design and patient population
Between June 2010 and January 2013, primary care patients aged between 60-85 years, with 
an International Classification of Primary Care for hypertension (K86 or K87) as captured 
from their medical record, were recruited from five general practices affiliated with the 
primary care organization PoZoB (a primary care organisation of approximately 200 GPs, 
located in the South of The Netherlands) for this cross-sectional study. Exclusion criteria 
were: previous diagnosis of heart failure, current treatment by a cardiologist, history of 
severe psychiatric illness other than mood/anxiety disorders and/or cognitive impairments 
(e.g. dementia), terminal cancer, and insufficient knowledge of the Dutch language. This 
study was approved by the medical ethics committee of the Elisabeth Hospital in Tilburg, 
The Netherlands.
Study procedure and data collection
Eligible patients received written information about the study by mail and were asked 
to sign an informed consent form. In case of informed consent patients were contacted, 
and an appointment for an interview at their local GP office was scheduled. This interview 
consisted of a structured interview of one hour by a trained nurse. At the end of the intake, 
an appointment for the echocardiogram was scheduled which also took place at the local 
GP office. 
Measurements
Demographic and clinical variables
Information on demographic and clinical variables was obtained from purpose-designed 
questions in the interview and included gender, age, marital status, and educational level. 
Furthermore, blood pressure was measured twice and the average blood pressure was 
used to dichotomize systolic blood pressure (>160 mmHg was cut-off). Height and weight 
were measured in order to calculate the body mass index (BMI). Information on clinical 
variables retrieved from the patients’ medical records included myocardial infarction (MI) 
and peripheral arterial disease. 
Assessment of symptoms
Information on heart failure symptoms was obtained during the interview. Structured 
and standardized questions were used to assess heart failure symptoms. Symptoms were 
dichotomized (yes/no) and defined as; shortness of breath during moderate exertion (e.g. 
walking), regularly occurring fatigue, oedema of the legs, ankles and/or feet, having cold 
extremities, and restless sleep, during the past 4 weeks. 
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Assessment of the echocardiogram
The echocardiogram was performed and evaluated by an experienced echocardiographist 
of the local primary care laboratory located in Eindhoven, The Netherlands. All the 
echocardiograms were reviewed by a cardiologist specialized in echocardiography, who 
indicated if the echocardiogram was abnormal according to a protocol suitable for primary 
care, based on current guidelines.23,24 The definition of an abnormal echocardiogram is 
shown in Table 1.
Table 1. Prevalence of abnormal echocardiogram parameters in 591 elderly primary care hypertension patients 
Total (n=591)
Abnormalities on the echocardiogram
LAVI > 29 ml/m² 60 (10%)
LVEF <55% 51 (9%)
Valvular abnormalities 48 (8%)
LVH  septal and posterior wall thickness of ≥ 13 mm (moderate or severe) 36 (6%)
Diastolic dysfunction (E/A ratio of <1 and DTs of >200ms, and presence of LVH in case of 
grade I diastolic dysfunction)
35 (6%)
Wall motion abnormalities (hypokinesia, akinesia and dyskinesia) 26 (4%)
RVH; subcostal wall thickness of  ≥6mm  (mild, moderate or severe) 15 (3%)
Total ≥1 abnormality 175 (30%)
LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; RVH, right 
ventricular hypertrophy; DT, deceleration time
Statistical analyses
Statistical analyses were performed using the IBM Statistical Package for the Social Sciences 
version 18.0. Differences in baseline characteristics were compared between normal and 
abnormal echocardiogram and assessed with Chi-square tests or Student’s/Welch’s T-tests 
when appropriate. For each symptom and clinical variable, the sensitivity, specificity, 
positive predictive value, and negative predictive value with 95% confidence intervals were 
calculated. 
Adjusted odds ratio’s were calculated using multiple logistic regression, with an abnormal 
echocardiogram (taking all cardiac abnormalities together) as dependent variable. A 
possible relation between symptoms and an abnormal echocardiogram were adjusted 
for age, gender, education, having a partner, previous MI, peripheral arterial disease, and 





From 6 different GP-practices, 913 eligible patients with hypertension were approached 
and 619 (68%) patients agreed to participate. Of these participants, 2 were excluded post-
hoc because they met the exclusion criterion of being treated by a cardiologist, 5 were 
excluded post-hoc because the echocardiogram was not of sufficient quality and 16 patients 
did not have an echocardiogram. Patients with congenital disease and/or hypertrophic 
cardiomyopathy were excluded from analyses (n=5), leaving a total of 591 (65%) patients 
for analysis.
Baseline characteristics
Table 2 shows the baseline characteristics. The mean age of the study patients was 70+/-
6.5 years and 44% was male (n=262). Patients with an abnormal echocardiogram were 
significantly older, did less often have a partner, were more likely to have had a previous 
MI, and had a higher systolic blood pressure as compared to the patients with a normal 
echocardiogram. Abnormalities on the echocardiogram were present in 30% of the study 
sample (Table 1).
Heart failure symptoms and abnormal echocardiogram
Restless sleep was the most prevalent symptom (25%, n=149). The most sensitive was 
shortness of breath with a sensitivity of 32%. The most specific symptom was oedema of the 
ankles, feet, or legs, with a high specificity of 90%. Oedema did also have the highest positive 
predictive value (45%) and negative predictive value (73%) for an abnormal echocardiogram 
(Table 3). 
In adjusted analysis (Table 4), oedema was significantly and independently related to an 
abnormal echocardiogram adjusted for age, sex, having a partner, the co-existence of type 
2 diabetes or peripheral arterial disease, systolic blood pressure >160 mmHg. The other 
symptoms were not significantly associated with an abnormal echocardiogram in adjusted 
analysis.
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Table 4. Correlates of abnormal echocardiogram in elderly primary care hypertension patients (adjusted analysis; 
N=587)
Unadjusted analysis Odds ratio (95% CI) P-value
Demographics
Female gender .87 (.61-1.23) .423
Age 1.07 (1.04-1.10) <.001
Having a partner .60 (.41-.89) .012
Clinical history
Previous myocardial infarction 3.71 (1.68-8.16) .001
Peripheral arterial disease 2.26 (.98-5.22) .057
Systolic blood pressure >160 mmHg 1.70 (1.16-2.49) .006
Symptoms
Shortness of breath 1.17 (.74-1.85) .505
Fatigue 1.20 (.77-1.87) .428
Oedema of lower extremities 2.17 (1.33-3.53) .002
Cold extremities 1.45 (.97-2.17) .073
Restless sleep .84 (.55-1.26) .393
Adjusted analysis Odds ratio (95% CI) P-value
Demographics
Female gender .83 (.56-1.25) .378
Age 1.06 (1.03-1.09) <.001
Having a partner .71 (.46-1.11) .135
Clinical history
Previous myocardial infarction 3.00(1.28-7.03) .011
Peripheral arterial disease 1.44 (.70-4.37) .230
Systolic blood pressure >160 mmHg 1.62 (1.08-2.41) .019
Symptoms
Shortness of breath .90 (.53-1.53) .702
Fatigue .92 (.54-1.56) .763
Oedema of lower extremities 2.12 (1.23-3.64) .007
Cold extremities 1.30 (.84-2.01) .240
Restless sleep .95 (.61-1.50) .836
Discussion
The current study shows that regular restless sleep was reported by 25%, having cold 
extremities by 23%, fatigue by 19%, shortness of breath by 17%, and oedema of legs, ankles 
and/or feet by 13%. An abnormal echocardiogram was present in 30%.  Oedema is an 
important symptom of cardiac dysfunction as reflected by an abnormal echocardiogram; 
the positive predictive value of oedema was 45%, the sensitivity 20%, and specificity 90%. 
In adjusted analysis, oedema was the only symptom that was significantly associated with 
abnormal echocardiogram apart from higher age, previous MI, and a systolic blood pressure 
of >160 mmHg. The symptoms shortness of breath, fatigue, having cold extremities, and 
having restless sleep were of limited value in predicting an abnormal echocardiogram.
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Strengths and limitations
This study is among the first to evaluate the value of heart failure symptoms in the diagnosis 
of cardiac dysfunction in unselected elderly primary care hypertension patients. Since 
hypertension is one of the most important risk factors for incident heart failure3 and elderly 
hypertension patients represent a large proportion of patients in whom cardiovascular risk 
management is crucial, the results of this study are very relevant. Furthermore, by using 
echocardiography, we studied the association between symptoms and cardiac abnormalities 
associated with heart failure including left ventricular dysfunction, diastolic dysfunction, 
LVH, and valvular dysfunction, while a majority of research evaluated the association of 
symptoms and left ventricular systolic dysfunction only, not taking into account other 
cardiac dysfunctions predictive of heart failure.8
Some methodological issues need consideration. First, the cross-sectional design of the study 
does not allow for evaluation of the course of symptoms in relation to cardiac dysfunction. 
Second, the study population was primarily Caucasian (99%) limiting generalizability to 
other populations with more ethnic diversity. Another limitation is that we do not have 
detailed demographic information of the non-responders. However, the response rate in 
the current study was almost 70%. Moreover, the current design was not used to assess 
prevalence figures but rather to evaluate whether signs and symptoms could be associated 
with echocardiogram outcome. 
Comparison with existing literature
Previous research showed that the most common symptoms associated with heart failure 
are oedema, dyspnea, and fatigue.14,15 However, most previous studies looking at the value 
of symptoms in the diagnosis of heart failure used selected samples of patients who were 
referred because of symptoms, mostly including patients who already reported dyspnea.25 
For example, patients in the study of Davie et al. were referred for diagnosis of heart failure 
and the large majority was referred because of symptoms (dyspnea), and the symptom 
oedema had no predictive value and low sensitivity and specificity.19 In another primary 
care study in patients with suspected heart failure based on a questionnaire and a physical 
examination, similar findings were reported; oedema had limited value in the diagnosis of 
heart failure, and as in the current study no other symptoms were associated with heart 
failure diagnosis.17 However, the latter study excluded patients who visited for a specialized 
consultation including hypertension consults, which limits the possibility to generalize 
the results to hypertension patients. Furthermore, other studies assessing the diagnostic 
accuracy of dyspnea found heterogeneous results, and conclude that symptoms and 
signs are of limited use for ruling out heart failure primarily because of a low sensitivity.25 
Especially in early stages of heart failure, milder symptoms do occur which are generally 
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insensitive in the diagnosis of heart failure.6 Nevertheless, a diagnostic tool for heart failure 
in primary care was developed, based on a systematic review. According to this research, 
patients who present themselves with symptoms of heart failure (e.g. breathlessness) are 
most at risk when there is a history of MI, basal crepitations present, and the patient is male 
with ankle oedema. The inclusion of oedema in this tool is more in line with our findings, 
however, this tool was developed for populations of patients with already suspected heart 
failure with presentation of symptoms,26 and therefore this tool is most likely not suitable 
for unselected elderly primary care hypertension patients.
Although breathlessness is the most commonly reported symptom in established heart 
failure in primary care,16 our findings showed that oedema, and not shortness of breath, 
was significantly and independently associated with cardiac dysfunction as reflected by an 
abnormal echocardiogram, together with previous MI, higher age, and elevated systolic 
blood pressure. However, oedema had a low sensitivity making it less useful for ruling out 
cardiac dysfunction in elderly hypertension patients. The low sensitivity of all symptoms in 
our study can possibly be explained by the mild severity of cardiac dysfunction, with the 
majority of patients not reporting any symptoms.
Implications
In the majority of cases the GP is involved in the initial diagnosis of heart failure.16 Therefore, 
attention to cardiac dysfunction predictive of chronic heart failure is important, especially in 
primary care populations at increased risk. The echocardiogram is the most useful test in the 
assessment of chamber volumes, systolic, and diastolic function,6 and it is recommended 
by recent guidelines as a useful tool to evaluate LVH and left ventricular dysfunction.2 The 
results of our study show that oedema of the lower limbs is significantly associated with 
cardiac dysfunction on an echocardiogram in elderly hypertension patients, it has modest 
positive predictive value, but adequate specificity. Although the value of symptoms is 
limited in the diagnosis of heart failure,17 oedema of the lower limbs could be of diagnostic 
value. The presence of oedema in elderly hypertension patients could alert the GP to initiate 
further assessment of cardiac function by means of echocardiography. To conclude, it would 
be recommended for GPs to check for oedema and consider an echocardiogram for further 
diagnosis of cardiac dysfunction, especially in elderly hypertension patients with a poorly 
controlled systolic blood pressure and/or a previous MI. 
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Chapter 5
Prevalence of Psychological 
Distress in Elderly Hypertension 
Patients in Primary Care
Ringoir L, Pedersen SS, Widdershoven JWMG, Pop VJM




Background: Recent guidelines on cardiovascular disease prevention advocate the 
importance of psychological distress, as they contribute to the risk of developing 
cardiovascular disease. However, most previous research on psychological distress and 
cardiovascular factors has focused on selected populations with cardiovascular disease.
Aim: The primary aim was to determine the prevalence of depression, anxiety, and Type D 
personality in elderly primary care patients with hypertension. The secondary aim was to 
examine the relation between elevated systolic blood pressure and depression, anxiety, and 
Type D personality.
Design and Setting: A cross sectional study in primary care practices located in the South of 
the Netherlands.
Method: Primary care hypertension patients (n=605), between 60-85 years (45% men, mean 
age=70±6.6), were recruited for this study. All patients underwent a structured interview 
including validated self-report questionnaires to assess depression (PHQ-9), anxiety (GAD-
7), and Type D personality (DS14) as well as blood pressure assessment.
Results and Conclusion: Depression was prevalent in 5%, anxiety in 5%, and Type D 
personality in 8%. None of the distress measures were associated with elevated systolic 
blood pressure of >160 mmHg (all p-values >0.05). This study showed no relation between 
psychological distress and elevated systolic blood pressure in elderly primary care patients 
with hypertension.
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Introduction
Hypertension is an important risk factor for cardiovascular disease, such as coronary artery 
disease (CAD), heart failure and stroke1 with the mean prevalence of hypertension in six 
European countries being 44% (50% in men, 39% in women).2 Systolic blood pressure 
increases with age, with the mean systolic blood pressure (SBP) of European citizens aged 
60-64 years exceeding 140 mmHg, which increases to a mean SBP of 150 mmHg for those 
aged 70-74 years.2 
One of the key messages in the 2012 European guidelines on cardiovascular disease 
prevention in clinical practice is that assessment of psychosocial factors such as depression, 
anxiety, and Type D personality (the tendency to experience negative emotions combined 
with the tendency to inhibit expression of emotions3) in patients with cardiovascular 
disease (CVD) risk factors is crucial, as they contribute to the risk of developing CVD.4 
However, more recent and larger studies have reported smaller or no effects of Type D 
personality on cardiovascular outcomes or mortality as compared to earlier studies.5 A 
recent systematic review showed an increased incidence of hypertension in individuals 
with elevated symptoms of depression.6 In contrast with the European guidelines4 and 
cardiac rehabilitation where screening for anxiety and/or depression is recommended,7 
psychological factors are not included in the multifactorial8 Dutch primary care guidelines 
on Cardiovascular Risk Management.9
In patients with hypertension, psychological distress may serve as a barrier against adequate 
medication adherence.10 Prior findings have shown an independent association between 
poor medication adherence in elderly patients with hypertension and depression and 
anxiety.10,11 In general, adherence is considered paramount for the successful treatment of 
hypertension, with non-adherence as one of the possible causes of resistant hypertension.12 
The objectives of the current study were to examine (1) the prevalence of symptoms of 
depression, anxiety and Type D personality in elderly primary care patients with hypertension, 
and (2) the relation between elevated symptoms of depression, anxiety, Type D personality, 
and systolic blood pressure.
Methods
Participants and design
Between June 2010 and January 2012, primary care patients aged between 60-85 years with 
diagnosed hypertension according to their medical records were recruited for this cross-
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sectional study from five general practices affiliated with the primary care organization 
PoZoB. Exclusion criteria were: Previous diagnosis of heart failure, current treatment by 
a cardiologist, history of severe psychiatric illness other than mood or anxiety disorders, 
cognitive impairments, terminal cancer, insufficient knowledge of the Dutch language, 
illiteracy, or inability to read due to visual impairments. The study protocol was approved 
by the medical ethics committee of the Elisabeth Hospital, Tilburg, The Netherlands. All 
participants provided informed consent.
Measures
Demographic and clinical variables
Demographic variables assessed during a structured interview at the local general 
practitioner (GP) office included age, gender, education level, and marital status. Clinical 
variables assessed during the structured interview included height, weight, blood pressure 
(after 20 and 40 minutes of resting), current smoking, alcohol consumption, current or 
past depression, and current or past anxiety. Information on clinical variables obtained via 
chart extraction and using International Classification of Primary Care codes were previous 
myocardial infarction, peripheral arterial disease, cerebrovascular accident or transient 
ischemic attack (CVA/TIA), chronic obstructive pulmonary disease (COPD), type 2 diabetes, 
and years since diagnosis of hypertension. 
Psychological measures
Psychological distress was assessed with patient-report questionnaires which were filled 
out during the structured interview. The 14-item Type D Scale (DS14) was used to assess 
Type D personality with 7 items tapping into negative affectivity (NA) and 7 items into social 
inhibition (SI). Items are rated on a 5-point Likert scale. The SI and NA scales can be used as 
continuous scales (range 0-28), and also to classify patients as “Type D” versus “non-Type 
D”, using a cut-off of 10 on both NA and SI that was found to be optimal according to item 
response theory.13 The DS14 is a valid and reliable instrument to assess Type D personality.14 
Symptoms of depression were measured with the Patient Health Questionnaire-9 (PHQ-
9). The nine items are rated on a 4-point Likert scale (range 0-27). For this study a cut off 
of ≥9 was used, since it is considered suitable for elderly individuals in primary care, with 
a sensitivity of .88 and specificity of .80, and an area under the curve for the detection 
of a major depressive disorder of .87.15 Symptoms of anxiety were measured with the 
Generalized Anxiety Disorder-7 (GAD-7) scale. The seven items are rated on a 4-point Likert 
scale (range 0-21). A cut-off of ≥8 has a high sensitivity and specificity for the detection of 
generalized anxiety disorder (sensitivity=.92 and specificity=.76) as well as for the detection 
of any anxiety disorder (sensitivity=.77 and specificity=.82), the area under the curve for 
detecting generalized anxiety disorder is .91.16
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Both the PHQ-9 and the GAD-7 are derived from the Primary Care Evaluation of Mental 
Disorders (PRIME-MD), which was originally designed for the diagnosis of five mental 
disorders (depression, anxiety, alcohol abuse, somatoform disorder, and eating disorder) in 
the primary care setting by using DSM IV criteria.17
Statistical analyses
Statistical analyses were performed using IBM Statistical Package for the Social Sciences 
version 18.0. Because previous research has shown differences in prevalence of depression 
and anxiety between men and women, the different psychological indices are reported 
for the total group and for men and women separately.18 Student’s t-tests or Welch’s 
t-tests (two-tailed) were used to assess differences in mean scores between groups when 
appropriate. Unadjusted odds ratio’s were calculated using univariable logistic regression 
analysis, with an elevated systolic blood pressure >160 mmHg as dependent variable which 
was calculated using the mean of the two blood pressure assessments. Adjusted odds 
ratio’s were calculated using multiple logistic regression, also with an elevated systolic 
blood pressure >160 mmHg as dependent variable and elevated symptoms of depression, 
anxiety, and Type D personality, as independent variables, adjusting for age, gender, having 
a partner, education, current smoking, alcohol consumption, and BMI.
Results
Of 913 patients with hypertension approached, 619 (68%) agreed to participate. Fourteen 
patients were excluded post-hoc as they met the exclusion criterion of being treated by 
a cardiologist (n=2), missing all PHQ-9, GAD-7, and DS14 scores (n=1), and insufficient 
knowledge of the Dutch language (n=11). This resulted in 605 patients (66%) that could be 
included in the analyses. The baseline characteristics for the total sample and stratified by 
systolic blood pressure ≤160 mmHg and >160 mmHg, are shown in Table 1. The mean age 
was 70 years (±6.6) and 45% of the study population was male. 
An elevated systolic blood pressure of >160 mmHg was found in 29% of the patients (n=174). 
A systolic blood pressure of >160 mmHg was associated with higher age (p=.006), regular 
alcohol consumption (p=.006), and an elevated diastolic blood pressure of >90 mmHg 
(p<.001). Using the age categories 60-70 years, 70-80 years, and 80-85 years, prevalence 
of elevated systolic blood pressure increased significantly with age (p=.018, Figure 1). The 
proportion of males and females was similar in both participants and non-participants. 
Women who refused participation were significantly older (p < .001).
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Male 270 (45%) 186 (43%) 84 (48%) .251
Age (mean ± SD) 70.0 (6.6) 69.5 (6.5) 71.1 (6.5) .006
Having a partner 455 (75%) 323 (75%) 132 (76%) .812
Low educational level 78 (13%) 50 (12%) 28 (16%) .136
Risk factors
Smoking 81 (13%) 55 (13%) 26 (15%) .476
Alcohol consumption ≥ 2 glasses a day (on average) 194 (32%) 124 (29%) 70 (40%) .006
BMI kg/m² (mean ± SD, n=600) 28.0 (4.4) 28.1 (4.5) 27.9 (4.2) .628
Medical history
Years since diagnosis (mean ± SD) 12.3 (11.2) 11.8 (10.2) 13.6 (13.1) .105
Diastolic blood pressure >90 mm/Hg 126 (21%) 52 (12%) 74 (43%) <.001
Previous myocardial infarction 27 (5%) 20 (5%) 7 (4%) .739
Peripheral arterial disease 23 (4%) 15 (4%) 8 (5%) .515
TIA/stroke 55 (9%) 38 (9%) 17 (10%) .712
Diabetes type II 68 (11%) 52 (12%) 16 (9%) .312
SBP, systolic blood pressure; BMI, body mass index; TIA, transient ischemic attack











Between 60 and 70
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Between 70 and 80
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As shown in Table 2, the prevalence of depression using a cut-off score of (≥9) on the PHQ-
9 was 5%, of anxiety using a cut-off of ≥8 on the GAD-7 5%, and of Type D personality 8% 
when using a cut-off of ≥10 on both the negative affectivity and social inhibition subscales 
of the DS14. Women had significantly higher mean depression, anxiety, and negative affect 
scores than men.
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Table 2. Prevalence and mean scores of depression, anxiety, and Type D in 605 elderly primary care hypertension 
patients stratified by gender
Total sample Men Women P-value
Prevalence
Depression (PHQ-9 ≥9) 30 (5%) 6 (2%) 24 (7%) .006
Anxiety (GAD-7 ≥8) 31 (5%) 11 (4%) 20 (6%) .293
Type D personality* 49 (8%) 15 (6%) 34 (10%) .041
Mean scores
Depression symptoms (PHQ-9 total score) 2.2 (3.0) 1.5 (2.4) 2.7 (3.4) <.001
Anxiety symptoms (GAD-7 total score) 1.9 (2.9) 1.4 (2.6) 2.2 (3.1) .001
DS14 negative affect 4.3 (4.8) 3.2 (4.3) 5.1 (5.1) <.001
DS14 social inhibition 6.0 (5.7) 5.7 (5.3) 6.3 (5.9) .207
*a score of ≥10 on both the negative affect and social inhibition subscales
In the unadjusted analysis (Table 3), age (OR=1.038, 95% CI=1.010-1.066) and regular alcohol 
consumption (OR=1.666, 95% CI=1.154-2.407) were significantly associated with a systolic 
blood pressure of >160 mmHg. Depression, anxiety and Type D personality were not related 
to high systolic blood pressure. Adjusted logistic regression showed that age (OR=1.042, 
95% CI=1.011-1.073) and regular alcohol consumption (OR=1.661, 1.121-2.426) were 
significantly related to a systolic blood pressure of >160 mmHg (Table 3). Again there was 
no association with depression, anxiety, and Type D personality, adjusting for age, gender, 
marital status, low education, current smoking, regular alcohol consumption, and BMI. 
Table 3. Associates of systolic blood pressure of >160 mmHg in elderly primary care hypertension patients
Unadjusted analysis OR 95% CI
Female gender .813 .571-1.158
Age 1.038 1.010-1.066
Having a partner 1.051 .697-1.583
Low education 1.461 .886-2.410
Current smoking 1.201 .726-1.988
Alcohol consumption ≥ 2 glasses a day (on average) 1.666 1.154-2.407
BMI .990 .951-1.031
Type D personality* 1.347 .727-2.495
Depression (PHQ-9 ≥9) .907 .396-2.078
Anxiety (GAD-7 ≥8) .855 .375-1.950
Adjusted analysis
Female gender .879 .598-1.293
Age 1.042 1.011-1.073
Having a partner 1.300 .821-2.059
Low education 1.425 .837-2.428
Current smoking 1.416 .826-2.428
Alcohol consumption ≥ 2 glasses a day (on average) 1.661 1.121-2.462
BMI .999 .958-1.041
Type D personality* 1.563 .805-3.038
Depression (PHQ-9 ≥9) .950 .370-2.437
Anxiety (GAD-7 ≥8) .863 .339-2.196




The results of this study indicate a low prevalence of psychological distress in an unselected 
sample of elderly primary care hypertension patients. Elevated symptoms of depression 
were found in 5%, elevated symptoms of anxiety in 5%, and Type D personality was prevalent 
in 8% of the study population. We found no association between elevated symptoms of 
depression, anxiety, Type D personality and an elevated systolic blood pressure.
The prevalence of depression in the current study is in line with a large study on depression 
in later life in which the prevalence of depression in adults aged between 55 and 85 years 
was 2% for major depressive disorder and 13% for minor depression.19 In general up to 50% 
of patients with moderate to high scores on the PHQ-9 do have a major depression,20 which 
would imply that 2.5% of the patients in the current study could have a major depression. A 
review on generalized anxiety disorder in primary care has indicated a prevalence between 
3% and 9%, which is similar to our findings.21 Results of a population based study showed 
a decline in the prevalence of depression, anxiety, and Type D personality with higher age. 
This is in line with our results on the prevalence of depression and anxiety, however, Type 
D personality was prevalent in 17% of their study population of elderly individuals which 
is more than twice as much as compared to our study.22 Another previous study on Type D 
personality, also in primary care hypertension patients with a mean age of 60, found a very 
high prevalence of Type D personality (53%).14 This is in contrast to our findings of a Type D 
prevalence rate of only 8%. Another Dutch population based study showed a prevalence of 
Type D personality of 13%,23 which is more in line with the results of our study, indicating 
that prevalence rates of Type D personality may vary markedly amongst different studies 
and populations. 
The 2012 European guidelines on cardiovascular disease prevention underline the importance 
of psychological factors in the risk of developing cardiovascular disease.3,4 However, there 
is no evidence that depression treatment reduces cardiovascular events,24 and there is an 
ongoing debate about the added value of screening for depression in patients with CVD.24,25 
Nevertheless, depression in patients with cardiovascular disease is not only associated with 
clinical outcomes, but also with adherence and poorer health status and impairments to 
quality of life independent of disease severity.26 
The association between hypertension and distress found in previous research could be 
explained by decreased adherence to antihypertensive medication.10,11 However, although 
as many as 28.9% of the patients in the current study had an elevated systolic blood pressure 
of >160 mmHg, there was no significant association with depression, anxiety, and Type D 
personality. These findings suggest that other factors contribute to poor blood pressure 
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control in elderly patients with hypertension, at least in primary care. The current findings 
are in line with the results from Friedman et al., who demonstrated no significant difference 
in depression and anxiety between normotensive and mildly hypertensive participants.27 
Furthermore, the relatively low prevalence of depression in the current study as well as 
the lack of an association with elevated systolic blood pressure, is also in accordance with 
the findings of Wiehe et al. who also did not find a higher prevalence of hypertension in 
depressive individuals.28
A major strength of this study is the relatively large sample size of an unselected, elderly 
hypertension cohort in the primary care setting. The high prevalence of hypertension 
indicates that (elderly) hypertension patients represent a large proportion of primary care 
patients where cardiovascular risk management is recommended.2
A limitation of the study is the cross-sectional design, which does not allow to draw 
conclusions about causation or to evaluate symptoms over time. Furthermore, there were 
only limited data available on patients who refused participation. It is possible that patients 
who refused participation were more likely to be depressed and anxious, and more likely 
to have a Type D personality.29 Furthermore, the Type D construct as a prognostic indicator 
for cardiovascular outcomes is the subject of some debate.30 Initially published studies 
have reported higher odds ratios for Type D personality as a predictor of mortality and 
cardiovascular outcomes as compared to more recent studies in which more events were 
reported, which could possibly imply an overestimation of the effect of Type D personality 
on mortality or cardiovascular events.5 Finally, depression and anxiety were measured by 
means of self-report measures rather than a clinical diagnostic interview. However, the PHQ-
9 and the GAD-7 are highly validated instruments with good psychometric properties,13-16 
and self-reported symptoms of depression and anxiety have been shown to predict cardiac 
morbidity and mortality in cardiac populations.31,32 
In conclusion, a low prevalence of symptoms of anxiety, symptoms of depression, and Type 
D personality was found in the current study. Furthermore, this study shows no relation 
between depression, anxiety, and Type D personality and an elevated systolic blood pressure. 
Therefore, prospective research in primary care populations with hypertension is needed 
to evaluate the evolvement of psychological distress in association with hypertension over 
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Background and objectives: Previous findings regarding a possible association between 
beta-blocker use and depression are mixed. To our knowledge there have been no studies 
investigating the association of beta-blockers with depression in primary care hypertension 
patients without previous myocardial infarction. The aim of this study was to determine the 
relation between lipophilic beta-blocker use and depression in elderly primary care patients 
with hypertension. 
Methods: A cross sectional study in primary care practices located in the South of the 
Netherlands. Primary care hypertension patients without previous myocardial infarction or 
heart failure (N=573), aged between 60 and 85 years (mean age=70±6.6), were included. 
All patients underwent a structured interview that included a self-report questionnaire to 
assess depression (PHQ-9), which was divided in 4 groups (PHQ-9 score of 0, 1-3, 4-8, 9 or 
higher). 
Results: A PHQ-9 score of 0 was more prevalent in non-beta-blocker users versus lipophilic 
beta-blocker users (46% vs. 35%), a PHQ-9 score of 4-8 was less prevalent in non-beta-
blocker users as compared with lipophilic beta-blocker users (14% vs. 25%). A Chi2 test 
showed that lipophilic beta-blocker users as compared to non-beta-blockers users were 
more likely to be in a higher depression category (p=.012). Ordinal regression showed a 
significant relationship between use of lipophilic beta-blockers and depression (OR=1.60, 
95%CI:1.08-2.36) when adjusting for potential confounders. 
Conclusion: Our findings show that primary care hypertension patients who use a lipophilic 






Worldwide the prevalence of hypertension in the adult population is approximately 26%, 
and the number of adults with hypertension is expected to increase with 60% by 2025.1 
In a Dutch sample of 591 elderly individuals (60-70 years), hypertension was prevalent in 
62%.2 In the Netherlands, once the diagnosis of hypertension has been confirmed and no 
secondary causes are indicated, most primary care hypertension patients are treated by a 
practice nurse in conjunction with the general practitioner (GP).
For hypertension patients with concomitant coronary artery disease (CAD) and/or previous 
myocardial infarction (MI), beta-blockers are recommended by the current guidelines, 
while beta-blockers are not first choice treatment of hypertension without concomitant 
cardiac disease.3 Although beta-blockers are still popular in primary care, the use has been 
associated with (severe) side effects including fatigue and fluid retention.4,5 
There is an ongoing debate whether beta-blockers may lead to depression, but evidence 
for an association between beta-blocker use and depression is mixed. A recent review 
concluded that many studies are subject to methodological shortcomings that might explain 
the mixed findings.6 However, some recent studies with substantial sample sizes, assessing 
depression with validated instruments, have not found a clear association between beta-
blockers and depression,7-9 or did even find a reduced risk of depression with beta-blocker 
use.10 However, these studies focused on patients with established heart disease, including 
patients treated with percutaneous coronary intervention (PCI), with angina pectoris,10 with 
an implantable cardioverter defibrillator (ICD),7 or patients who recently had an MI.9 The 
results of the study of van Melle et al. showed no association between beta-blocker use at 
discharge and symptoms of depression at 3, 6 and 12 months, but they found a significant 
association between beta-blocker use and symptoms of depression before admission to the 
hospital. This association remained significant even after controlling for confounders such as 
hypertension and previous MI.9 To our knowledge, only the study of Luijendijk et al. selected 
elderly people with and without cardiac disease and/or hypertension.8 This study found an 
association between highly lipid-soluble beta-blockers and depression in the first 90 days of 
use, however, the effect disappeared after 90 days. 
To our knowledge there have been no studies investigating the association of beta-blockers 
with depression in hypertension patients in primary care without a previous MI or heart 
failure. Because lipophilic beta-blockers are still prescribed frequently in primary care 
hypertension patients - although current guidelines advocate other medications as first-line 
treatment - more insight into the possible adverse effects can provide valuable information 
for clinicians. In the current study, we investigated the association between lipophilic beta-
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blocker use and depression in elderly primary care hypertension patients without heart 
failure or a previous MI, taking into account potential confounders, including the use of 
benzodiazepines, antidepressants, and other factors such as comorbidities that may impinge 
on this relationship. 
Methods
Participants and study design
Between June 2010 and January 2013, primary care patients aged 60-85 years, with 
diagnosed hypertension in their medical record, were recruited for this cross-sectional 
study from five different general practices affiliated with the primary care organization 
PoZoB. The patient population predominantly lives in a semi-rural area in the Southern part 
of The Netherlands. Patients were excluded in case of a previous diagnosis of heart failure 
and/or currently being treated by a cardiologist, a history of severe psychiatric illness other 
than mood or anxiety disorders, cognitive impairments (e.g. dementia), terminal cancer, 
insufficient knowledge of the Dutch language, or illiteracy or inability to read due to visual 
impairments. The study protocol was approved by the Medical Ethical Committee of the St. 
Elisabeth Hospital, Tilburg.
Study procedure 
Eligible patients were selected from the GPs’ patient records (n=913), received information 
about the study via postal mail and were contacted by telephone. In case of informed consent 
an appointment for an intake at the local GP office was planned. This intake consisted of a 
structured interview, including patient-reported questionnaires, by a nurse at the local GP’s 
office.
Measurements
Demographic and clinical variables
Information on demographic and clinical variables obtained from purpose-designed 
questions during the interview included gender, age, marital status, employment, 
educational level (less than high school education vs. high school education or higher), 
previous episode(s) of depression, life style habits (BMI, current smoking, alcohol intake). 
Information on clinical variables obtained from the patients’ medical records included MI, 
peripheral arterial disease, cerebro-vascular accidents or transient ischemic attack (CVA/





The prevalence of depressive symptoms was assessed with the Patient Health Questionnaire 
9 (PHQ-9). The PHQ-9 is a self-report questionnaire that consists of nine questions tapping 
into the DSM-IV criteria for a major depressive episode, with answers indicated on a 
four point Likert scale with a range of 0-27, with a higher score indicating more (severe) 
symptoms. The PHQ-9 has been validated in elderly primary care populations, with a cut-off 
of ≥9 indicative of major depression.11 
Statistical analyses
Statistical analyses were performed using the IBM Statistical Package for the Social Sciences 
version 18.0. Lipophilic beta-blocker users were compared with non-beta-blocker users 
or hydrophilic beta-blockers users (n=13) in the analysis. Chi2 tests were used to examine 
differences between groups on nominal variables. Student´s t-tests were used for continuous 
variables or Welch’s t-test when the equal variances assumption could not be met. 
Due to non-normality of the outcome variable (PHQ-9 total score), the scores on the PHQ-9 
were divided into 4 categories: (1) score of 0 (n=247, 43%), (2) score of 1-3 (n=198, 35%), 
(3) score of 4-8 indicative of mild depression (n=100, 918%), and (4) score of 9 or higher 
which is indicative of moderate depression (n=28, 5%).11 A Chi2 test was used to examine 
the unadjusted difference between lipophilic beta-blocker users and non-lipophilic beta-
blocker users in PHQ-9 score categories (df=3). Ordinal regression was performed to assess 
the adjusted relation between lipophilic beta-blocker use and depression (PHQ-9 score 
categories).12 Multicollinearity was checked prior to the adjusted ordinal regression using 
Spearman’s Rho. All non-parametric correlations were <.400, indicating no problems with 
multicollinearity. Furthermore the parallel lines as well as the goodness of fit assumptions 
for ordinal regression were met. The 4 PHQ-9 score categories were entered into the ordinal 
regression as dependent variable. The independent variable was lipophilic beta-blocker use 
and other possible confounders were: Age, female gender, low education (less than high 
school education), marital status (being single/no partner), being employed, type 2 diabetes, 
CVA/TIA, COPD/asthma, arthritis, peripheral arterial disease, current smoking, regular 
alcohol consumption (≥2 glasses a day), history of depression, number of antihypertensive 
medications, benzodiazepine use, and antidepressant use.
Results
Sample characteristics
For this study, 913 elderly hypertension patients were approached of whom 619 (68%) 
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agreed to participate. Another 46 patients were excluded post-hoc because they were 
currently treated by a cardiologist (n=2), had missing data on medication use (n=6), were 
not of Dutch origin and had difficulty understanding the Dutch questionnaires (n=11), or 
had a previous MI (n=27).  Finally, 573 patients (63%) were included in the analyses. Table 
1 shows that nearly one third (n=164, 29%) of the hypertension patients used a lipophilic 
beta-blocker (metoprolol, propranolol, bisoprolol, pindolol, carvedilol, nebivolol), with 
metoprolol being the most frequently prescribed (79%). Patients who used a lipophilic beta-
blocker were more likely to use calcium channel blockers (p=.006) as compared to non-beta-
blocker users (including 13 hydrophilic beta-blocker users; atenolol, celiprolol, sotalol). 
Lipophilic beta-blocker use and depression (unadjusted analysis)
Figure 1 shows that a PHQ-9 score of 0 was more common in the non-beta-blocker users 
(n=189, 46%) as compared with lipophilic beta-blocker users (n=58, 35%). A score on the 
PHQ-9 of 4-9 was more common in lipophilic beta-blocker users (n=41, 25%) as compared 
with non-beta-blocker users (n=59, 14%). Lipophilic beta-blocker use was reported in 24% of 
the patients with a PHQ-9 score of 0, in 28% of the patients with a PHQ-9 score 1-3, in 41% 
of patients with a PHQ-9 score 4-8, and in 32% of patients with a PHQ-9 score of 9 or higher 
(data not shown in table). The overall Chi2 test showed a significant difference between 
PHQ-9 categories and lipophilic beta-blocker use (df=3; p=.012). 
Figure 1. PHQ-9 scores in categories stratified by lipophilic beta-blocker use






































































































































































































































































































































































































































































































































































































































































































































































Beta-blocker use and depression (adjusted analysis)
Table 2 shows the results of the ordinal regression analysis with 4 categories of PHQ-
9 scores as dependent variable, and age, sex, low education, single/no partner, being 
currently employed, type 2 diabetes, COPD/asthma, CVA/TIA, peripheral arterial disease, 
arthritis, current smoking, regular alcohol consumption, history of depression, number 
of antihypertensive medications, benzodiazepine use, antidepressant use, and lipophilic 
beta-blocker use as independent variables. In this adjusted analysis, use of lipophilic beta-
blockers (OR=1.60, 95% CI:1.08-2.36) was a significant independent associate of depression 
together with age (OR=.96, 95% CI:.93-.99), female gender (OR=1.68, 95% CI:1.19-2.38), 
having no partner (OR=2.30, 95% CI:1.55-3.40), asthma/COPD (OR=2.39, 95% CI=1.39-
4.11), previous depression (OR=1.64, 95% CI=1.02-2.66), and benzodiazepine use (OR=2.75, 
95% CI=1.46-5.17). When examining a dose response relationship between lipophilic beta-
blocker use and depression, no significant differences were found between a low dose 
(below recommended dose) or the recommended dose or higher (data not shown). 
Table 2. Adjusted ordinal regression with lipophilic beta-blocker use as independent variable and PHQ-9 
categories* as dependent variable in 573 elderly primary care patients with hypertension
Odds ratio 95% Confidence interval
Demographics
Age .96 .93-.99
Female gender 1.68 1.19-2.38
Low education 1.32 .81-2.15
Single/no partner 2.30 1.55-3.40
Current employment 0.64 .38-1.10
Comorbidities
Type 2 diabetes 0.98 .58-1.66
TIA/stroke 0.95 .53-1.70




Current Smoking 1.37 .85-2.21
Regular alcohol use (≥ 2 glasses per day) 0.82 .57-1.17
Previous depression 1.64 1.02-2.66
Medication
Number of antihypertensive medications 0.99 .82-1.19
Benzodiazepines 2.75 1.46-5.17
Antidepressants 1.70 .83-3.49
Lipophilic beta-blocker 1.60 1.08-2.36
*Category (1) score of 0, (2) score of 1-3, (3) score of 4-8, (4) score of 9 or higher. 





Summary of main findings
To our knowledge, this is the first study examining the relationship between lipophilic beta-
blocker use and depression in primary care hypertension patients without previous MI 
or heart failure after adjusting for “classical” associates of depression. This study shows 
a relation between the use of lipophilic beta-blockers and depression as compared to 
non-beta-blocker use. Overall, a significant association was found between lipophilic beta-
blocker use and symptoms of depression (as divided into 4 categories). Patients with a 
lipophilic beta-blocker had more often a score on the PHQ-9 between 4 and 9 - indicative 
of mild depression13 - as compared with non-beta-blocker users. It is well known that the 
use of benzodiazepines in the elderly is associated with unrecognized depression may even 
precede symptoms of depression.14 Therefore this was an important potential confounder 
to take into account when looking at an independent association between lipophilic beta-
blocker use and depression.6 Interestingly, diabetes was not associated with depression, 
which is not in line with previous findings.15 An association was found between having COPD 
or asthma and depression, which has previously been reported in a recent meta-analysis.16 
Strengths and limitations
This study has some limitations. First, the cross-sectional design does not allow for making 
any inference about cause and effect. Second, although the PHQ-9 is a reliable instrument 
to assess depressive symptoms,13 symptoms are not identical to a depressive disorder. 
Furthermore, fatigue is a common side-effect of beta-blocker use,17,18 which is also one of 
the symptoms of depression and included in the PHQ-9.13 It might be speculated whether 
the elevated depression scores are a reflection of side-effects related to the use of beta-
blockers. However, regardless of the origin of the depressive symptoms, patients in our 
study using lipophilic beta-blockers reported after adjustment for possible confounders 
higher depression scores which implies that beta-blockers either are associated with mood 
directly or produce side effects that contribute to higher depression scores.
This study also has several strengths. To our knowledge, this is the first study to investigate 
the association of lipophilic beta-blockers with depression in primary care hypertension 
patients without previous MI or heart failure. As summarized in a recent review, the literature 
shows rather conflicting results regarding a possible association between depression and 
beta-blockers, and a majority of these studies had methodological shortcomings, such as 
using antidepressant treatment as a proxy for depression.6 However, antidepressants are 
given for other conditions than depression, including anxiety.19 Most of the aforementioned 
methodological shortcomings were all tackled in our study including assessment of 
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depression with a standardized and validated questionnaire, sufficient sample size, and 
taking into account confounders that could possibly impinge on the relation between beta-
blocker use and depression. 
Comparison with existing literature
According to the Dutch primary care guidelines for cardiovascular risk management, beta-
blockers are not the primary choice of drug therapy for the treatment of hypertension. 
Only in case of intolerance to other antihypertensive medications, a beta-blocker should be 
considered as a sufficient alternative, however, common adverse effects of beta-blockers 
should be taken into consideration.20 In our study, 29% of the hypertension patients 
without a previous MI used a lipophilic beta-blocker, with the majority using metoprolol. 
Because lipophilic beta-blockers can pass through the blood-brain-barrier, they are most 
likely to be associated with side-effects associated with the central nervous system such as 
depression.18 This was supported by the findings of the current study, as use of lipophilic 
beta-blockers was associated with increased symptoms of depression. As reported in earlier 
studies, lipophilic beta-blockers, including the medium lipid-soluble metoprolol which 
was prescribed most often in our study, can affect the central nervous system resulting in 
adverse effects such as sleeping problems or changes in mood.18 Furthermore, previous 
research showed an association between symptoms of depression and high lipid-soluble 
beta-blockers. However, this effect was only present in the first 90 days of use and the 
specific association between medium lipid-soluble selective beta-blockers and depression 
was not studied because these were taken together with low lipid-soluble beta-blockers 
in the analysis.8 In three other studies with reliable assessment of depression, sufficient 
sample size, and adjustment for other correlates of depression, no association was found 
between beta-blocker use and depression.7,9,10 Because these studies included patients with 
cardiac disease for whom prescription of a beta-blocker is recommended3,21-23, a possible 
explanation of the difference in findings could be that in patients with cardiac disease the 
beneficial effects beta-blockers surpass the adverse effects.  
Implications
In conclusion, we found a significant relationship between the use of lipophilic beta-blockers 
and depression scores in primary care hypertension patients without previous MI or heart 
failure when adjusting for potential confounders. Our findings underline the recommendation 
of the most recent guidelines with respect to being cautious with prescribing beta-blockers 
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Background and scope of the thesis
The rationale for this thesis is based on the need to gain insight into the clinical and 
psychological aspects of hypertension management in elderly patients in primary care. 
This thesis provides information on how hypertension is currently managed in Dutch 
primary care, which patients have abnormalities on an echocardiogram, the value of heart 
failure symptoms in the detection of patients at risk for having cardiac abnormalities on 
the echocardiogram, and which psychological issues are associated with hypertension and 
antihypertensive treatment. In this chapter, the main findings of the thesis are summarized, 
methodological considerations are presented, and implications for clinical practice and 
future directions are discussed. 
Main results and conclusions
Hypertension management and screening in primary care
The Dutch multidisciplinary guideline on cardiovascular risk management (CVRM) describes 
a target systolic blood pressure (SBP) for hypertension patients of ≤140 mmHg, with the 
exception of patients aged 80 years an older with a target SBP of ≤160 mmHg, and patients 
with diabetes with a target SBP of ≤130 mmHg. A progressive stepwise scheme is described 
with antihypertensive medications to lower SBP. Diuretics are recommended as medication 
of first choice, with calcium channel blockers (CCB) as second option in case of side effects. 
However, angiotensin converting enzyme (ACE) inhibitors as well as angiotensin II receptor 
blockers (ARBs) are equally effective for the prevention of cardiovascular events as compared 
to CCBs and diuretics.1 As a second step, a combination of a diuretic and an ACE-inhibitor 
can be considered, with replacement by an ARB in case of side effects. A third option is the 
combination of a diuretic with an ACE inhibitor or ARB, and a CCB. Beta-blockers are only 
recommended in case of side effects to one of the antihypertensive medications described 
above.2
Adequate treatment of hypertension, and therefore adherence to the guideline on CVRM, 
is important because starting at a SBP of 115 mmHg, an increase of 20 mmHg doubles the 
risk of cardiovascular morbidity and mortality.3 We studied the adherence of the GPs from 
five practices to the Dutch CVRM guideline in 568 primary care patients with hypertension 
(excluding those with previous myocardial infarction (MI) and/or atrial fibrillation) aged 
between 60 and 85 years. As indicated by the results presented in chapter 2, the majority of 
these patients (67%) had inadequate blood pressure control according to the Dutch CVRM 
guideline (SBP>140mmHg, or SBP>130mmHg in patients with type 2 diabetes, or SBP>160 
mmHg in patients aged 80 years and older),2 and 29% of patients had a SBP of >160 mmHg 
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(stage 2 hypertension4). The results showed that only 58% of the patients were managed 
appropriately according to the guideline. Furthermore, 21% of patients treated according 
to the guideline had an abnormal echocardiogram compared to 37% who were not treated 
according to the guideline. In logistic regression analysis, the association between treatment 
according to the guideline and an abnormal echocardiogram remained highly significant, 
after adjusting for age, gender, education, current smoking, regular alcohol consumption, 
body mass index, type 2 diabetes, years since diagnosis of hypertension, and SBP. 
American guidelines on CVRM have described that early assessment of cardiovascular 
risk can enhance individualized efforts to prevent cardiovascular disease.5 Symptomatic 
heart failure is generally preceded by asymptomatic cardiac dysfunction or changes in 
cardiac structure such as left ventricular hypertrophy (LVH).6,7 According to the current 
European Society of Cardiology (ESC) guidelines on diagnosis and treatment of chronic 
heart failure, echocardiography is a useful tool to assess chamber volumes, ventricular 
systolic and diastolic dysfunction, wall motion, wall thickness, and valvular function.8 No 
data are available on the prevalence of abnormal cardiac outcomes in (elderly) primary care 
hypertension patients. Therefore, the aim of chapter 3 was to screen primary care patients 
with hypertension aged between 60 and 85 years for cardiac abnormalities as reflected by 
an abnormal echocardiogram. The results showed that 30% of patients (n=181) had one 
or more abnormalities on the echocardiogram. The most prevalent abnormalities were 
a dilated left atrium (left atrium volume index >29ml/m2; 10%), reduced left ventricular 
ejection fraction (<55%; 9%), LVH (6%), and diastolic dysfunction (6%). Older age and a SBP 
of >160 mmHg were independently and significantly associated with cardiac abnormalities 
on the echocardiogram. 
The feasibility of echocardiography in a primary care setting, the high prevalence of 
abnormalities on the echocardiogram, and the availability of (simple) interventions imply 
that screening of elderly hypertension patients by means of echocardiography could be 
very relevant. However, it is desirable to identify hypertension patients at risk in whom 
further examination by means of echocardiography is indicated. In the majority of cases 
the general practitioner (GP) is involved in the initial diagnosis of heart failure.9 The value 
of symptoms, such as shortness of breath, fatigue, and edema, for the diagnosis of heart 
failure seems to be limited.10 However, previous research mainly focused on patients who 
were selected because of already existing symptoms11 and/or did not include all cardiac 
abnormalities associated with heart failure.12 To be able to identify patients at risk for cardiac 
dysfunction, the focus of chapter 4 of this thesis was to evaluate the diagnostic value of 
heart failure symptoms (shortness of breath, edema, fatigue, cold extremities and restless 
sleep) in unselected primary care hypertension patients aged between 60 and 85 years. 




or legs was the most important symptom with a positive predictive value of 45%. Edema 
was significantly and independently associated with cardiac dysfunction as reflected by an 
abnormal echocardiogram together with higher age, previous MI, and a SBP of >160 mmHg. 
Psychological factors in hypertension in primary care
Currently, psychological distress, such as depression, anxiety, and Type D personality, is 
receiving increasing attention due to its high prevalence in patients with cardiovascular 
disease and impact on cardiovascular prognosis.13 For example, a previous meta-analysis 
showed that depression is prevalent in approximately 20% of heart failure patients, and is 
associated with higher risk for morbidity and mortality.14 Another meta-analysis showed 
an association between anxiety and higher incidence of coronary heart disease (26%) 
and higher cardiac mortality risk (48%).15 Although hypertension patients in primary care 
represent a large group at risk for cardiovascular disease, research on psychological distress 
conducted in this patient group is scarce. Furthermore, results of previous research on a 
possible association between depression and hypertension are inconclusive.16-19 Therefore, 
chapter 5 reported on the prevalence of depression, anxiety, and Type D personality in 
elderly primary care hypertension patients and examined the relation between elevated 
SBP (>160 mmHg) and depression, anxiety, and Type D personality. The results showed a 
prevalence of 5% for depression, 5% for anxiety, and 8% for Type D personality. There was 
no association between depression, anxiety, and Type D personality and elevated SBP. 
Finally, according to the progressive scheme on use of antihypertensive medication in the 
Dutch guideline on CVRM, the role of beta-blockers has been reduced in comparison with 
previous guidelines.2 Several studies have shown inferior effectiveness of beta-blockers 
as compared to other antihypertensive medication in reducing cardiovascular risk in 
hypertension patients without previous MI.1,20 In addition, beta-blockers are associated with 
(severe) side effects such as fatigue and fluid retention.21,22 Furthermore, there is ongoing 
debate concerning the association between lipophilic beta-blockers and depression.23 
Despite the minor role of beta-blockers in the current guideline on CVRM, lipophilic beta-
blockers are still frequently prescribed in primary care hypertension patients. Therefore, 
in chapter 6 we studied the association between the use of lipophilic beta-blockers and 
depression in primary care hypertension patients. Our results indicated a significant 
association between lipophilic beta-blockers and symptoms of depression after adjusting 




Design of the study
In all studies described in this thesis, we used a cross-sectional design, which limits the 
possibility to draw conclusions regarding causality. Hence, for example we cannot directly 
conclude that the abnormal echocardiogram as reported in chapter 3 will result in poorer 
cardiovascular outcomes as compared to patients with no abnormal echocardiogram. 
However, previous prospective studies have already unequivocally shown an increased risk 
of future major adverse cardiovascular events in patients with for example an enlarged left 
atrium,24,25 diminished left ventricular ejection fraction,21, left ventricular hypertrophy,26 or 
diastolic dysfunction,27 which were the most prevalent abnormalities that we found on the 
echocardiogram. Overall, the results of this thesis should be viewed as preliminary and as 
a first step in elucidating the potential importance of the current CVRM guideline and a 
possible inclusion of echocardiography in the standard procedure of CVRM. 
Participants and study setting
A large sample of primary care hypertension patients was included in this study (n=619). 
Patients completed a comprehensive interview including purpose designed questions on 
demographic information, standardized questionnaires on heart failure symptoms, and 
standardized and validated questionnaires on psychological distress. The extended focus 
of the interview and the extensiveness of the information gathered on the participating 
subjects allowed for controlling for potential confounders. Furthermore, all patients were 
assessed with echocardiography providing information on cardiac dysfunction. Because 
patients included in this study were not selected based on signs or symptoms of heart failure, 
and not treated by a cardiologist, the prevalence of abnormalities on the echocardiogram 
might be generalized to elderly primary care hypertension patients in general, and not 
only to those in whom cardiac dysfunction is expected. A study limitation is the limited 
data available on the non-participants, which hampers the possibility of generalizing our 
results to the total population of elderly hypertension patients in primary care. However, 
the majority of patients (70%) approached for study participation agreed to participate, and 
the available characteristics (age and sex) of the non-participants were similar to the study 
population, except for the age of the non-participating women, as they were on average 3 
years older. 
Around the time of inclusion of patients into the study, the participating practices were 
all starting up a CVRM program. This program aims to prevent (secondary) cardiovascular 
events and includes structural follow-up by the GP and a practice nurse, multidisciplinary 




patient included in this program. Currently, approximately 45.000 patients are included 
in the CVRM program of PoZoB, of whom the majority (65%) has hypertension. Since the 
majority of the patients included in the study as described in this dissertation met the 
criteria of inclusion in this CVRM program, the sample included in this study can been seen 
as a subsample representative of the hypertension patients aged between 60 and 85 years 
included in the CVRM program. Furthermore, the distribution of age and sex were very 
similar in the study sample as compared with the total population hypertension patients 
between 60 and 85 years included in the CVRM program of PoZoB.  
Measures
Based on previous research, echocardiography is recommended for the detection of both 
LVH and left ventricular systolic dysfunction in patients at risk for heart failure.28,29 In our 
study, a broad spectrum of cardiac dysfunction was found by echocardiography. A strong 
point of our study is that echocardiography is seen as the gold standard for confirming a 
diagnosis and establishing the cause of heart failure.8,21 All the echocardiograms in our 
study were reviewed by a cardiologist specialized in echocardiography, who indicated if the 
echocardiogram was abnormal according to a protocol suitable for primary care, based on 
current echocardiography guidelines.30,31 The echocardiogram was performed in the local 
general practice with a mobile echocardiography system, which made the echocardiogram 
easily accessible to all participating patients. In addition, the costs of such an echocardiogram 
are not high (€75), enhancing the feasibility of implementing echocardiogram screening as 
part of the CVRM in general practice. 
In the diagnosis of major depressive or anxiety disorder, a diagnostic interview is considered 
the gold standard. However, a diagnostic interview is expensive and time-consuming. 
Therefore, in chapter 5 and chapter 6 we used the self-report 7-item General Anxiety 
Disorder scale (GAD-7) and the 9-item Patient Health Questionnaire (PHQ-9) to assess 
symptoms of anxiety and depression. For the detection of generalized anxiety disorder a 
cut-off of ≥8 has a high sensitivity and specificity, the area under the curve for detecting 
generalized anxiety disorder is .91.32 For the detection of a major depressive disorder as 
described in chapter 5, a cut off of ≥9 was used, since it is considered suitable for elderly 
individuals in primary care. This cut-off also has a high sensitivity and specificity, and an 
area under the curve of .87.33 Both the PHQ-9 and the GAD-7 were developed for use in the 
primary care setting, and mirror the DSM IV criteria for depressive or anxiety disorder.34,35 
Furthermore, we used categories of depression scores to assess the association between 
lipophilic beta-blockers and depression. A limitation of our studies in chapter 5 and 6 was 
that depressive symptoms are not identical to depressive disorder, as elevated depression 
scores are not equivalent to having a depressive disorder. Nevertheless, previous research 
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has shown that approximately 50% of patients with moderate or high scores on the PHQ-9 
do have major depression.36 Lipophilic beta-blocker users had more often depression scores 
indicative of mild depression, and less often no symptoms of depression in comparison with 
non-beta-blocker users. Furthermore, several symptoms of depression as described in DSM 
IV34 and assessed by the PHQ-9 are very general (e.g. fatigue, problems with sleeping, having 
trouble with concentrating) and might be explained by side-effects of beta-blockers. It is still 
unclear whether increased scores on the PHQ-9 are symptoms of depression or a reflection 
of drug side effects. Future prospective studies are warranted to unravel the association 
between beta-blocker use and depression in hypertension patients. 
Practical and clinical implications
Screening of hypertension patients
The results of the studies described in chapter 2 and chapter 3 showed a high prevalence 
of cardiac dysfunction assessed with echocardiography, with a significant and independent 
association between cardiac abnormalities on the echocardiogram and SBP as well as an 
association with treatment according to the current Dutch guideline on CVRM. 
According to the guideline for appropriate use of echocardiography, initial and general 
evaluation of cardiac structure function and routine evaluation of hypertension without 
symptoms or signs of hypertensive heart disease with echocardiography is discouraged.37 
The use of echocardiography to evaluate suspected hypertension related heart disease is 
recommended by this guideline.37 Since the value of symptoms and signs in the diagnosis 
of heart failure is limited, especially in early stage heart failure, many patients with (early) 
cardiac dysfunction might not be diagnosed. Whether all hypertension patients of 60 
years and older should be screened with echocardiography remains a subject of debate. 
Only prospective research could elucidate whether patients really benefit from screening. 
However, benefit from screening is not unlikely when perusing literature on progression 
from for example LVH or diastolic dysfunction to heart failure. Progression from stage A 
(only risk factors) and stage B (cardiac dysfunction without symptoms) heart failure  to stage 
C (overt) heart failure is associated with a dramatic (5-fold) decrease in 5-year survival.6 
Furthermore, for example in patients with diastolic dysfunction, ACE-inhibitors and ARBs 
have been shown to be more effective in improving diastolic filling as compared to other 
antihypertensive medication.38 In our study, based on the echocardiogram, the specialized 
cardiologist not only reported the outcome of the echocardiogram to the GP but also 
advised the GP when to take further action. For approximately 50% of the patients with an 




consisting of adding or changing to an angiotensin converting enzyme (ACE) inhibitor or to 
increase the dose of the antihypertensive medication. Other advice consisted of referral to 
a cardiologist in the hospital setting (24%) or follow-up with an echocardiogram within 1 to 
5 years (22%). Moreover, the outcomes of the echocardiogram, including the advice of the 
cardiologist, were sent automatically to the GP. In every practice, the cardiologist visited 
at least once during the project to provide the GPs with information on echocardiography 
and the importance of the most prevalent abnormalities. The participating GPs generally 
experienced this as a valuable addition to the screening. Furthermore, the results in chapter 
4 showed that patients with edema were at increased risk for having abnormalities on the 
echocardiogram. Based on these results we can recommend GPs and practice nurses to 
check for edema and possibly request an echocardiogram in these patients, especially when 
this is accompanied by elevated SBP.
In the current study, most of the WHO criteria for screening, as indicated by Wilson and 
Jungner, were met.39 Overt heart failure is a major health problem,6 and often preceded 
by asymptomatic cardiac dysfunction resulting from hypertension such as LVH or diastolic 
dysfunction.40 In the focused update of the American Heart Association guidelines for 
diagnosis and management of heart failure, the importance of early detection of heart failure 
is emphasized, with the aim of introducing therapeutic interventions before the appearance 
of left ventricular dysfunction or symptoms in order to reduce population morbidity and 
mortality of heart failure.21 Furthermore, echocardiography is important for determining 
the cause of heart failure as well as to establish appropriate treatment.8 
Cardiovascular risk management in hypertension
Optimal blood pressure control was only found in a minority of the patients. However, this 
project was initiated when the CVRM program had just started, underlining the importance 
of a structured program in which hypertension management plays an important role. It is 
not unlikely that this program might result in improvements of CVRM in general, as well 
as specific hypertension management in the near future. A recent report written by the 
primary care organizations PoZoB and De Ondernemende Huisarts (DOH), who developed 
the CVRM program together, showed positive preliminary results with 30% of the patients 
experiencing a decrease in SBP of ≥10 mmHg after 3 years in the CVRM program.41  It is well 
known that a decrease of 10 mmHg will result in an absolute risk reduction for cardiovascular 
events of 22%.42
How should we attain systolic blood pressure control?
The World Health Organization stated in “A global brief on hypertension” that early detection, 
adequate treatment, and good control of hypertension is paramount to gain health benefits 
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and economic benefits.43 Achieving blood pressure control is important, but generally only 
observed in approximately 20-54% of hypertension patients as reported in several studies 
in Europe.44-47 The Dutch guideline on CVRM specifically emphasizes that patients with 
inadequate SBP control require the most attention and care.2 Chapter 2 depicts that most 
of the hypertension patients aged between 60-85 years had suboptimal SBP control (71%), 
and would therefore warrant extra attention and care. Furthermore, 39% of the patients 
in our sample were not treated according to the current guideline. Although the design of 
our study does not allow us to draw conclusions about causality, it is at least remarkable 
that the prevalence of abnormalities on the echocardiogram is 21% in patients who 
were treated according to the current Dutch guideline versus 37% in patients not treated 
according to the guideline, with the risk of abnormalities being almost 2-fold. Furthermore, 
in previous research inadequate treatment has been described to be an important reason 
for uncontrolled hypertension.48 This underlines the importance of following the stepwise 
scheme for antihypertensive medication choice2 and prescribe adequate dosages. A 
structured CVRM program including hypertension management could play an important 
role in achieving better blood pressure control and outcomes in hypertension patients, as 
supported by previous research. An Australian randomized controlled trial showed that 
intensive structured care for primary care hypertension patients resulted in significantly 
better blood pressure control after 26 weeks in comparison with a control group who 
received usual care.49 Moreover, a Cochrane review studying interventions used to improve 
control of blood pressure in patients with hypertension showed the importance of using a 
systematic approach to deliver care for hypertension, including regular review and intensified 
antihypertensive drug treatment when necessary. Recently, a report on the PoZoB and DOH 
CVRM program has indicated that in patients with a SBP of >160 mmHg in whom no decline 
of SBP of ≥10 mmHg is reached, 25% did not use antihypertensive medication versus 12% in 
the group with a decline of ≥10 mmHg.41 
The effect of beta-blocker therapy in treatment of hypertension has been the subject of 
debate. A review and meta-analysis showed that beta-blockers were (slightly) inferior to 
other antihypertensive medication in the treatment of hypertension and associated with 
poorer compliance due to side effects.20 On the other hand, another meta-analysis found 
all antihypertensive drug classes to be equally effective, also in patients with hypertension 
without a history of cardiovascular disease.50 Irrespectively, beta-blockers remain important 
in the treatment of patients with a previous MI and/or atrial fibrillation.51 Taking these 
findings into account, the guideline on CVRM has given beta-blockers a less prominent role 
in the treatment of (uncomplicated) hypertension.2 Although we cannot conclude from 
the results of chapter 6 that beta-blockers directly lead to depression, they seem at least 




be related to the central nervous system. These findings support the recommendation in the 
CVRM guideline to be cautious with prescribing beta-blockers as the first-line medication for 
the treatment of hypertension. 
Should we screen for psychological distress in hypertension?
In the European guidelines on cardiovascular disease prevention in clinical practice, 
psychological distress (including depression, anxiety, and Type D personality) has been 
described as a contributor to cardiovascular risk as well as to worse prognosis in patients 
with established cardiovascular disease, and might also be a possible barrier for adherence.13 
Prior findings have shown an independent association between poor medication adherence 
in elderly patients with hypertension and depression and anxiety, which might be a possible 
explanation of the association between psychological distress and blood pressure.52,53 Our 
results showed a low prevalence of psychological distress and we found no association 
between depression, anxiety, and Type D personality and elevated SBP. These findings are 
in line with other previous research that found no association between depression, anxiety 
and hypertension.17,19 Furthermore, previous research in primary care diabetes patients not 
using insulin therapy has shown that the likelihood of depression was doubled but only in 
patients with multiple vascular co-morbidities, while the prevalence of depression in the 
patients with one or no vascular co-morbidity was similar to the general population.54 It 
seems that higher depression rates might be associated with (multiple) chronic diseases. 
Moreover, a study in systemic sclerosis patients showed that patients score approximately 1 
point higher on the somatic items of the PHQ-9 (fatigue, sleep difficulties, appetite problems, 
psychomotor agitation/retardation) as compared with non-medically ill respondents.55 
Similar findings were reported in a study with post-MI patients who scored more than 
one point higher on somatic symptoms of the Beck Depression Inventory in comparison 
with psychiatric outpatients with no previous MI who were matched on cognitive-affective 
symptoms scores, sex, and age.56 The association between depression and cardiovascular 
outcomes might possibly be explained by disease severity and complications, and therefore 
be more prominent in patients with established (cardiovascular) disease. Therefore, 
conventional risk factors as well as severity of the disease should be taken into account 
in future studies.57 Our findings do not directly suggest that primary care hypertension 
patients should be screened for psychological distress. Moreover, there is no evidence that 
depression treatment reduces cardiovascular events, which in part has led to an on-going 
debate about the added value of screening for depression in patients with cardiovascular 
disease.58,59 Nevertheless, GPs and/or nurses should still be alert and attentive to signs of 
psychological distress because patients with depression and/or anxiety might be less likely 
to be compliant with treatment, and psychological distress has a negative impact on overall 




One of the most important and general recommendations for future research resulting from 
this thesis would be to study the course of SBP prospectively within the CVRM program. Future 
research should focus on the development of heart failure in primary care hypertension 
patients, taking into account heart failure symptoms as well as cardiac dysfunction as 
reflected by an abnormal echocardiogram. It might be interesting to study whether patients 
with a longer duration of elevated SBP, despite being treated for hypertension, would be 
at greater risk for having cardiac abnormalities on an echocardiogram than patients with a 
shorter period of elevated SBP. Knowing exactly how hypertension evolves into heart failure 
would provide valuable information for clinical practice. Furthermore, when keeping the 
results of chapters 2 and 3 in mind, a prospective study could provide us with information 
on whether patients who are treated strictly according to the current Dutch guideline 
would have better outcomes as compared to those who were not, possibly differentiating 
between choice of medication and doses of medication. The CVRM program of PoZoB in 
which nearly 45.000 patients are included might provide prospective data for example 
regarding treatment according to the guideline in association with outcomes. Prospective 
research would also be recommended when studying psychological distress as a contributor 
to cardiovascular risk and/or adherence to antihypertensive medication. However, with the 
low prevalence and lack of association of psychological distress with elevated SBP in our 
study, the role of psychological distress in elderly primary care hypertension patients might 
be small.
Another future direction might be to introduce telehealth to manage hypertension, as 
self-monitoring of blood pressure might contribute to blood pressure control.61 Recently, a 
meta-analysis indicated that better blood pressure control in hypertension patients treated 
in several different settings using home blood pressure telemonitoring is more likely to be 
obtained than if patients receive usual care. Blood pressure telemonitoring also resulted 
in better physical health status in a subset of the studies included in the meta-analysis. 
Intervention operating costs, however, contributed to significantly higher costs in the group 
that received blood pressure telemonitoring.62 Nevertheless, healthcare benefits from 
lowering SBP, including reducing the risk for cardiovascular disease, would probably become 
apparent after a longer follow-up period. Recently, similar findings were reported for the 
effect of home blood pressure telemonitoring in a primary care setting on the short-term 
(i.e., 6 months follow-up), showing significantly improved blood pressure in comparison with 
a control group with also higher costs.63 Future research should reveal the long-term effects 
of telemonitoring for hypertension patients on blood pressure outcomes, cardiovascular 





This thesis has shown that almost one third of ‘relatively healthy’ primary care 
hypertension patients between 60 and 85 years had clinically relevant abnormalities on an 
echocardiogram, increasing their risk for developing heart failure. These findings reflect that 
there is still room for improvement with respect to the management of hypertension in 
primary care patients aged between 60 and 85 years. Screening of hypertension patients 
in primary care for echocardiographic abnormalities seems feasible, in particular if a 
cardiologist advices GPs what further action is required based on the echocardiography 
results. Echocardiography screening might be a valuable addition to CVRM for hypertension 
patients, although prospective research is needed to study the effect on cardiovascular 
outcomes. GPs and practice nurses should be attentive to edema, since this was associated 
with more abnormal echocardiograms in our study. Furthermore, our findings indicate 
that screening for psychological distress in primary care hypertension may at this point be 
premature until further evidence is available from prospective studies, since we found a 
low prevalence of psychological distress and no association with elevated SBP. This thesis 
underlines the importance of adherence to the guideline on CVRM.  A structured CVRM 
program - with promising preliminary results - might alter hypertension management 
and therefore possibly improve cardiovascular outcomes of a large group of primary care 
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Hypertensie komt vaak voor, vooral bij ouderen. In de internationale richtlijnen spreekt 
men van hypertensie bij een systolische bloeddruk van ≥140 mmHg en/of een diastolische 
bloeddruk van ≥90 mmHg. In Nederland komt hypertensie voor bij 61% van de  mannen en 
55% van de vrouwen in de leeftijdscategorie 60-70 jaar, oplopend tot ongeveer 70% bij beide 
in de leeftijdscategorie 70-80 jaar. Hypertensie is niet alleen een belangrijke risicofactor 
voor het krijgen van een beroerte of een TIA (transient ischemic attack), maar ook voor 
het ontwikkelen van verschillende hartafwijkingen (o.a. linker ventrikel hypertrofie en 
diastolische dysfunctie) die bijdragen aan de ontwikkeling van hartfalen (een ontoereikende 
pompfunctie van het hart). Om te voorkomen dat hypertensie zich ontwikkelt tot hartfalen 
is goede en gerichte behandeling belangrijk. Deze behandeling, zoals beschreven in zowel 
internationale richtlijnen als de Nederlandse Multidisciplinaire richtlijn Cardiovasculair 
Risicomanagement (CVRM), richt zich voornamelijk op het verlagen van de systolische 
bloeddruk. Systolische bloeddruk is een zeer belangrijke voorspeller van sterfte en het 
krijgen van cardiovasculaire ziekten, en verlaging van de systolische bloeddruk resulteert in 
een verminderd risico op het krijgen van cardiovasculaire ziekte of sterfte.
In de afgelopen decennia hebben zich in Nederland verschillende huisartsen-zorggroepen 
gevormd. PoZoB, met ongeveer 200 aangesloten huisartsen in de regio Zuidoost-Brabant, 
is één van de grotere zorggroepen in Nederland. In 2010 is PoZoB van start gegaan met 
een zorgprogramma CVRM. In dit zorgprogramma ontvangen patiënten gestructureerde 
zorg met als doel het risico op cardiovasculaire ziekte en sterfte te verlagen. Inmiddels 
zijn bijna 45.000 patiënten met een verhoogd risico en/of cardiovasculaire aandoeningen 
geïncludeerd in dit zorgprogramma. Het behandelen van hypertensie is hierin een belangrijk 
onderdeel.
Om inzicht te krijgen in klinische en psychologische aspecten van CVRM bij eerstelijns 
hypertensie patiënten, wordt in dit proefschrift de evaluatie beschreven van 1) de 
behandeling van hypertensie, 2) afwijkingen op het echocardiogram en 3) de relatie van 
deze afwijkingen met symptomen behorende bij hartfalen. Ook is in dit proefschrift gekeken 
welke psychologische aspecten mogelijk gerelateerd waren aan een matig tot ernstig 
verhoogde systolische bloeddruk (>160 mmHg). Daarnaast is de relatie tussen bètablokkers 




Voor het onderzoek beschreven in dit proefschrift zijn ruim 600 patiënten met hypertensie 
in de huisartsenpraktijk gescreend met de volgende inclusie criteria: 1) leeftijd tussen 
60 en 85 jaar oud, 2) geen diagnose hartfalen in het medisch dossier en 3) niet bij een 
cardioloog onder behandeling. Deze screening gebeurde door middel van een interview op 
de praktijk waarin vragenlijsten gericht op depressie, angst en Type D persoonlijkheid waren 
opgenomen. Ook werd het medisch dossier doorgelicht en een echocardiogram gemaakt 
waarmee hartafwijkingen werden vastgesteld. 
Volgens de internationale richtlijnen is het vroeg opsporen van hartafwijkingen en hartfalen 
cruciaal. Hierbij wordt het echocardiogram gezien als de gouden standaard in het vaststellen 
van hartafwijkingen behorend bij hartfalen, zoals linker ventrikel hypertrofie. In hoofdstuk 
2 van dit proefschrift is gekeken naar de samenhang tussen het hebben van een afwijkend 
echocardiogram en hypertensiebehandeling wel/niet volgens de huidige CVRM richtlijn. 
Deze richtlijn beschrijft welke medicatie gekozen kan worden en wanneer er medicatie zou 
moeten worden toegevoegd. Bij 38% van de deelnemende patiënten werd de behandeling 
niet (strikt) volgens de huidige richtlijn uitgevoerd. Deze groep bestond grotendeels uit 
patiënten die een bètablokker kreeg voorgeschreven. Uit de analyse bleek dat van de 
patiënten die wel volgens de huidige richtlijn behandeld werd 21% een afwijking had op het 
echocardiogram, van de patiënten die niet volgens de huidige richtlijn werden behandeld 
had 37% een afwijkend echocardiogram. Naast het hebben van een hogere leeftijd en/of een 
hogere systolische bloeddruk, hing het niet worden behandeld volgens de huidige richtlijn 
onafhankelijk samen met het hebben van een of meer afwijkingen op het echocardiogram. 
In hoofdstuk 3 wordt verder ingegaan op afwijkingen op het echocardiogram. In totaal had 
30% van de onderzochte groep een of meer belangrijke afwijkingen op het echocardiogram. 
Oudere patiënten met een systolische bloeddruk hoger dan 160 mmHg hadden een grotere 
kans om afwijkingen te hebben op het echocardiogram. De meest voorkomende afwijkingen 
waren een vergroot linker atrium (10%), verminderde linker ventriculaire ejectie fractie 
(9%), linker ventrikel hypertrofie (6%) en diastolische dysfunctie (6%). Deze vier categorieën 
werden gezien bij bijna 75% van de patiënten met afwijkingen op het echocardiogram 
en bij 22% van de totale groep onderzochte patiënten. Uit de literatuur blijkt dat al deze 
afwijkingen belangrijke voorspellers zijn voor het krijgen van hartfalen, en dat adequate 
behandeling dit risico duidelijk verlaagt. 
Huisartsen zijn vaak betrokken bij het vaststellen van (beginnend) hartfalen en het is 
daarom belangrijk om te weten welke symptomen van belang zijn in de signalering van 
beginnend hartfalen. Hoofdstuk 4 van dit proefschrift beschrijft de diagnostische waarde 
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van de symptomen kortademigheid, vermoeidheid, oedeem van de enkels, voeten en/
of onderbenen, rusteloze slaap en koude ledematen voor het hebben van een afwijkend 
echocardiogram. De resultaten lieten zien dat oedeem het belangrijkste symptoom was 
met een positief voorspellende waarde van 45% voor hebben van afwijkingen op het 
echocardiogram. 
Bij patiënten met cardiovasculaire aandoeningen is er steeds meer aandacht voor 
depressie, angst en Type D persoonlijkheid (de neiging om negatieve emoties te ervaren in 
combinatie met moeite om deze emoties te uiten naar anderen). Voorgaande onderzoeken 
- voornamelijk in tweedelijns populaties - laten zien dat depressie, angst en een Type D 
persoonlijkheid vaker voorkomen bij patiënten met cardiovasculaire aandoeningen en 
daarnaast ook gerelateerd kunnen  zijn aan een slechtere prognose. Omdat hypertensie 
een belangrijke risicofactor is voor het ontwikkelen van cardiovasculaire aandoeningen is in 
hoofdstuk 5 gekeken naar de prevalentie van depressie, angst en Type D persoonlijkheid bij 
oudere patiënten (60-85 jaar) met hypertensie in de huisartsenpraktijk. De resultaten lieten 
zien dat de prevalentie van depressie (5%), angst (5%) en Type D persoonlijkheid (8%) laag 
waren. Daarnaast werd er geen samenhang gevonden met het hebben van een verhoogde 
systolische bloeddruk.
De huidige CVRM richtlijn beschrijft een stappenplan voor de medicamenteuze behandeling 
van de systolische bloeddruk bij hypertensie patiënten. Bètablokkers zijn antihypertensiva 
die in de huidige richtlijn geen (eerste) voorkeur verdienen in de behandeling van 
hypertensie, en slechts worden geopperd in het geval van bijwerkingen van andere eerste 
keus medicatie zoals ACE-remmers of AII-antagonisten. Bètablokkers kunnen bijwerkingen 
zoals vermoeidheid veroorzaken en omdat lipofiele bètablokkers de bloed-brein-barrière 
kunnen passeren zouden ze mogelijk gerelateerd kunnen zijn aan depressieve symptomen. 
Eerdere onderzoeken laten tegenstrijdige resultaten zien met betrekking tot een mogelijke 
samenhang tussen het gebruik van bètablokkers en depressie. Omdat deze onderzoeken 
voornamelijk werden uitgevoerd bij patiënten met cardiovasculaire ziekte werd in hoofdstuk 
6 gekeken naar de samenhang tussen het gebruik van lipofiele bètablokkers en depressie bij 
hypertensie patiënten in de huisartsenpraktijk. Uit de resultaten bleek dat het gebruik van 
lipofiele bètablokkers - die nog veel worden voorgeschreven ondanks de bescheiden rol in 
de richtlijn - onafhankelijk samenhing met depressieve symptomen. 
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Hypertensie is een belangrijke risicofactor voor het krijgen van cardiovasculaire 
aandoeningen zoals hartfalen, en komt vaak voor bij ouderen. Adequate behandeling 
zoals beschreven in de Nederlandse multidisciplinaire richtlijn CVRM is daarom van groot 
belang. Dit wordt onderstreept door resultaten beschreven in dit proefschrift; bijna een 
derde van de onderzochte groep patiënten had een of meer belangrijke (klinisch relevante) 
afwijkingen op het echocardiogram. Daarnaast hadden veel patiënten niet de optimale 
systolische bloeddruk en hadden de patiënten met een hogere systolische bloeddruk 
en/of die niet volgens de huidige richtlijn behandeld werden een fors hogere kans om 
afwijkingen te hebben op het echocardiogram. Het onderzoek beschreven in dit proefschrift 
is cross-sectioneel. Longitudinaal onderzoek zal meer inzicht kunnen geven in hoe de 
echoafwijkingen zich in de tijd ontwikkelen en wat het effect is van adequate behandeling 
op het krijgen van cardiovasculaire aandoeningen en het risico op sterfte. Dit proefschrift 
laat zien dat de prevalentie van depressie, angst en Type D persoonlijkheid laag is bij oudere 
eerstelijns hypertensiepatiënten. Dit onderzoek geeft geen aanleiding voor extra aandacht 
voor depressie, angst en Type D specifiek voor oudere patiënten met hypertensie. Echter, bij 
patiënten die lipofiele bètablokkers gebruiken zou aandacht voor bijwerkingen waaronder 
symptomen van depressie wenselijk zijn.
Dit proefschrift geeft inzicht in verschillende aspecten behorende bij CVRM voor hypertensie 
patiënten die in de huisartsenpraktijk behandeld worden. Deze resultaten geven 
aanknopingspunten voor vervolgonderzoek en mogelijk ook voor de aandachtspunten binnen 







Na vier jaar hard werken is het tijd voor het laatste stukje van mijn proefschrift; het 
dankwoord. Er zijn veel mensen die direct of indirect een bijdrage hebben geleverd aan dit 
proefschrift. In dit dankwoord wil ik een aantal van hen in het bijzonder bedanken.
Allereerst wil ik graag alle patiënten bedanken die hebben meegewerkt aan het onderzoek. 
Bedankt voor het invullen van alle vragenlijsten en voor jullie deelname.
Professor Pop, beste Victor, ik kan niet anders dan je enorm dankbaar zijn voor je positiviteit 
en enthousiasme. Toen het in het begin allemaal even niet liep zoals we hadden gehoopt, 
heb jij ervoor gezorgd dat ik er toch de moed in hield. Tijdens het hele traject heb ik op jou 
kunnen vertrouwen en heb je me goed geholpen er de vaart in te houden (en het ook nog 
leuk te vinden!). Overleggen met jou waren altijd inspirerend en zorgden weer voor nieuwe 
energie. Bedankt!  
Professor Widdershoven, beste Jos, jij bent wat later op de al rijdende trein gesprongen, 
maar wat was ik blij met jouw cardiologische input en kennis. Ik heb erg veel van je geleerd 
en de rust die jij ondanks de drukte op de universiteit en in het ziekenhuis uitstraalde vond 
ik erg prettig. Bedankt voor je bijdrage.
Professor Pedersen, beste Susanne, jouw snelle en kritische feedback was altijd zeer welkom. 
Jij wist altijd met een enorm tempo mijn teksten nog even op te poetsen zodat alles lekker 
liep en er precies stond wat ik bedoelde. Bedankt voor jouw waardevolle bijdrage aan de 
totstandkoming van dit proefschrift. 
De leden van de beoordelingscommissie Prof. dr. A. Gorgels, Prof. dr. M. van Son, Prof. dr. J. 
Roukema, dr. W. Aarnoudse, dr. A. Lucas en dr. H. Kupper wil ik hartelijk bedanken voor de 
tijd die zij hebben genomen om dit proefschrift te lezen en te beoordelen en me te bevragen 
op 21 februari. 
De volgende co-auteurs van de artikelen in dit proefschrift wil ik graag bedanken: Arnold 
Romeijnders, Ben Imholz, Frans Pouwer, Josephine Keyzer, Jules Keyzer en Karim Hamraoui, 
bedankt voor jullie bijdrage.
Gedurende het project Chello heb ik met veel mensen mogen samenwerken die allemaal een 
zeer waardevolle bijdrage hebben geleverd aan het onderzoek. Allereerst de deelnemende 
huisartsen; ik ben erg blij dat we dit project zijn gestart in Vessem met Peter van Bommel 
en Jan Perik. Jullie enthousiasme en bereidwilligheid om mee te denken over hoe we onze 
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procedures beter konden laten verlopen was erg waardevol en heeft mede bijgedragen aan 
het succes van het project. Ook jullie assistentes zorgden ervoor dat ik me altijd welkom 
voelde op de praktijk. Ook wil ik graag Els Thissen, Corien van der Sluijs, Jos Ruskus, Pieter 
Hoff, Dre Daamen, Mariëlle van den Acker, Ylva Onderwater, Piet Adriaans en Joep van Rens 
bedanken voor hun deelname aan het project en de ruimte die zij in hun huisartsenpraktijk 
hebben gemaakt. Harrie van der Velde wil ik bedanken voor het maken van alle echo’s en 
de bereidwilligheid om altijd even tussendoor uitleg te geven over de betekenis van de 
echo’s. Paul Melman en Stephen Elshot wil ik bedanken voor de beoordeling van de echo’s 
en de cardiologische input. Lidewei, Esther, Anja en Corine bedankt voor jullie inzet in het 
interviewen van alle patiënten. Saffira, Antoine en Barbara dank voor jullie secure invoerwerk 
en Mirna voor het bellen en werven van deelnemers. Ook wil ik Anke Meulenbroeks, Karin 
Bekkering, Annelies Lucas en Jules Keyzer bedanken voor de prettige samenwerking met 
Diagnostiek voor U. Josephine, ik ben blij dat jij met de longitudinale gegevens aan de slag 
gaat en dat ik daar ook nog bij betrokken kan zijn, zodat we zoveel mogelijk resultaat uit dit 
project kunnen halen.
Nog voordat ik in Tilburg startte kon ik al even bij PoZoB aan de slag. Toen ik net begon, was 
ik soms overweldigd door de taken en verantwoordelijkheden die ik kreeg. Maar nu ben ik 
er erg dankbaar voor dat ik zoveel heb mogen doen en heb kunnen leren. Ik heb me altijd 
heel erg thuis gevoeld in Veldhoven en de huisartsenwereld is er een die ik erg boeiend vind. 
Ik wil graag Niels van Elderen, Arnold Romeijnders en Colette Wijnands-van Gent bedanken 
voor het in mij gestelde vertrouwen en de hulp en steun die ik in de afgelopen jaren van hen 
heb ontvangen. Niels, dank voor de kans om niet alleen mijn promotieonderzoek te mogen 
doen maar ook dat ‘boeiende’ Europese project. Arnold, jouw enthousiasme en focus op de 
inhoud, met de patiënt centraal, is erg inspirerend, bedankt! Colette, ik ben erg dankbaar 
voor jouw steun en hulp bij het managen van alles wat bij mijn projecten kwam kijken. Soms 
als ik dreigde te ‘verdrinken’ hielp jij altijd om weer de nodige structuur aan te brengen, en 
wat was het leerzaam (voor ons allebei)! Ik ben natuurlijk erg blij dat ik de kans heb gekregen 
om mijn tanden nu weer in nieuwe PoZoB-projecten te mogen zetten, dank daarvoor!  
Collega’s op de universiteit en bij PoZoB wil ik graag bedanken voor alle hulp en gezelligheid 
bij onze lunchwandelingen of theemomentjes tussendoor. De ‘wandelclub’ en mijn 
verschillende kamergenoten (Aly, Antoinette, Colette, Corinne, Corline, Esther, Jenny, Fleur, 
Helma, Giesje, Mariëlle, Marion, Mariska, Martha, Mirela, Moniek, Noortje, Olga en Simone) 
ben ik erg dankbaar voor alle steun en leuke momenten. Mirela, wij zijn samen begonnen 
en nu ook bijna tegelijkertijd klaar, dank voor de fijne eerste jaren op onze gezellige kamer. 
Antoinette, bedankt voor de leuke gesprekken en het grappige feit dat we af en toe wel erg 
dezelfde kledingsmaak hadden. Jenny, ik vond het erg fijn om bij je binnen te kunnen lopen 
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om onze zorgen of dat we het allemaal wel op tijd af zouden krijgen te kunnen delen. En we 
hebben het allebei toch voor elkaar gekregen! Mariëlle, dank voor de gezellige gesprekken 
op jullie kamer. Het was fijn om altijd binnen te kunnen lopen. Olga en Giesje, wat was het 
fijn dat jullie deur altijd open stond als ik even iets wilde vragen of gewoon even ‘afleiding’ 
nodig had. Martha, bedankt voor de opbeurende woorden en gezelligheid bij PoZoB, ik ben 
blij dat we nog steeds collega’s zijn! Helma en Moniek, mijn twee lieve kamergenootjes in 
het laatste anderhalf jaar. Ik vond het altijd erg fijn om met jullie op een kamer te zitten, 
inclusief de verhalen ‘uit de kliniek’ van Moniek op donderdagochtend ;).
Corinne en Marion, jullie zijn mijn paranimfen. Ik vind het erg fijn en ben jullie heel dankbaar 
dat jullie op 21 februari achter mij zullen staan. Lieve Corinne, wij waren al collega’s toen we 
nog bij het Trimbos Instituut werkten. En op de universiteit en zelfs ook bij PoZoB zaten we 
bij elkaar op de kamer. Bedankt voor jouw luisterend oor en interesse, ik vond het erg fijn om 
af en toe met je te sparren zodat ik zelf mijn ideeën weer een beetje op een rijtje kreeg. Ook 
dank voor de hulp bij de major revision die ik in de laatste 2 weken ook nog even voor elkaar 
moest krijgen. En natuurlijk ook bedankt voor je briljante boek-suggesties! Lieve Marion, ik 
ben jou erg veel dank verschuldigd. Omdat je een half jaar op me ‘voorliep’ heb ik veelvuldig 
gebruik kunnen maken van jouw ‘ervaringsdeskundigheid’, en natuurlijk de “0900-Marion-
lijn, voor al uw Excel vragen”. Nog belangrijker vind ik alle fijne gesprekken (inderdaad over 
van alles en nog wat) die we veelvuldig gevoerd hebben tijdens onze wandelingen en op 
onze werkplek bij PoZoB (waar we nu gelukkig nog steeds allebei zitten). 
Lieve vrienden, ik wil jullie heel erg bedanken voor de belangstelling en voor het meeleven. 
Ik ben blij dat ik zoveel steun en gezelligheid heb mogen ervaren in de afgelopen vier 
jaar. Het was erg fijn om naast het werk aan dit proefschrift ook andere dingen te kunnen 
doen zoals gezellige feestjes, etentjes/high teas, verscheidene bruiloften (inclusief die van 
onszelf) en vrijgezellenfeesten, bedankt allemaal! Ook wil ik Bettine bedanken voor de fijne 
dans-/pilates-/zumbalessen, jij hebt me geleerd mijn grenzen te verleggen. Roger en Linda 
(en jullie drie lieve meiden), bedankt voor jullie steun en alle fijne momenten die we in de 
afgelopen jaren hebben gehad. Dat er nog veel meer mogen volgen! Linda, een bijzondere 
dank voor jouw steun in de stressvolle periodes!
(Schoon)familie is erg belangrijk en heeft ook gezorgd voor veel fijne momenten in de 
afgelopen vier jaar. Bedankt Ad en Anneke, Ron en Nathalie, Mark en Louisa voor het 
meeleven en jullie belangstelling. Matthies, wat ben je toch een lieve broer, ik ben trots op 
je! Lieve Mama en Hans, heel erg bedankt voor jullie steun en interesse en natuurlijk alle 
gezellige momenten ‘met lekkere hapjes’ ;). Papa, wat is het toch fijn dat we bij elkaar ‘om 
de hoek’ wonen. Bedankt voor jouw onvoorwaardelijke steun en alle fijne momenten! 
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Dankwoord
Lieve Peter, terwijl ik dit dankwoord schrijf, zit jij achter de laptop tegenover mij de opmaak 
van mijn proefschrift te doen, allereerst dank daarvoor! Bedankt voor je hulp in deze soms 
erg drukke periode en voor je rust als ik weer eens liep te stressen. Zonder jou was het een 
stuk lastiger geweest! Ik ben zo blij met jou en geniet altijd van onze gezellige momenten 
tijdens vakanties, wandelingen, in de keuken en tijdens etentjes. Dankjewel voor je 
onvoorwaardelijke steun, je humor en je liefde.
Lianne, november 2013   
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